

Reference Committee K

BOT Report(s)

12 Information Regarding Animal-Derived Medications

Resolution(s)

- 901 Support for Preregistration in Biomedical Research
- 902 Increasing Patient Access to Sexual Assault Nurse Examiners
- 903 Regulating Front-of-Package Labels on Food Products
- 904 Support for Continued 9-1-1 Modernization and the National Implementation of Text-to-911 Service
- 905 Support Offering HIV Post Exposure Prophylaxis to all Survivors of Sexual Assault
- 906 Increased Access to Identification Cards for the Homeless Population
- 908 Increasing Accessibility to Incontinence Products
- 911 Regulating Tattoo and Permanent Makeup Inks
- 912 Comprehensive Breast Cancer Treatment
- 913 Addressing the Public Health Implications of Pornography
- 914 Common Sense Strategy for Tobacco Control and Harm Reduction

REPORT OF THE BOARD OF TRUSTEES

B of T Report 12-I-18

Subject: Information Regarding Animal-Derived Medications (Resolution 515-A-18)

Presented by: Jack Resneck, Jr., MD, Chair

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 INTRODUCTION

2
3 Resolution 515-A-18, "Information Regarding Animal Derived Medications," introduced by the
4 Michigan Delegation and referred by the House of Delegates (HOD) asked:

5
6 That our American Medical Association (AMA): (1) Support efforts to improve cultural
7 awareness pertaining to the use of animal-derived medications when considering different
8 prescription options. (2) Encourage the U.S. Food and Drug Administration to make available
9 to the public an easily accessible database that identifies medications containing ingredients
10 derived from animals.

11
12 Some chemical products used as inactive excipients for prescription drugs, as well as some active
13 prescription medications and also some surgical implants, dressings, and mesh, are derived from
14 animal sources. The consumption or use of such products may be objectionable to certain religions
15 or based on consumer choice. The objective of this report is to summarize the issue and current
16 evidence related to animal-derived components of medical products.

17 18 BACKGROUND

19
20 Some religious faiths forbid the consumption or use of certain animals and substances derived from
21 them. Additionally, individuals who adhere to a vegetarian or vegan diet may prefer to avoid
22 animal-derived medical products. Individuals who want to avoid animal-derived substances for
23 religious or cultural reasons may inquire about the origin or source of the ingredients in their
24 medical products for informed decision-making regarding treatment with the product. Frequently,
25 however, the information regarding ingredients or composition in medications is difficult to obtain
26 by physicians, pharmacists, and patients.¹

27
28 Many pharmaceutical products (both active and inactive ingredients used in capsules, tablets,
29 injections, vaccines, creams) and surgical products (implants, wound dressings, surgical mesh)
30 contain ingredients derived from animal sources. Animal-derived ingredients (ADIs) are used in
31 many medical fields and cover an array of products usually at minimal concentrations.¹ However, a
32 substantial percentage of patients and physicians are unaware that some medications and medical
33 products contain animal products;² one survey indicated that 84% of patients and 70% of
34 physicians were unaware that several medications contain ADIs. Additionally, 70% of physicians
35 thought it was important to inform patients who might object if such medications are prescribed.³
36 Some authors have even suggested obtaining informed consent before using animal-derived
37 products.¹

1 **POLICY AND LAW**

2
3 The U.S. Pharmacopeial Convention is a private, nongovernmental organization that publishes the
4 United States Pharmacopeia (USP) and the National Formulary (NF) as official compendia,
5 collectively called the USP-NF. The Federal Food, Drug and Cosmetic Act (FFDCA) expressly
6 recognizes the USP quality standards for medicines.⁴ Although much of the USP-NF is legally
7 enforceable, the USP chapters numbered above <999> are general information and generally do not
8 contain any mandatory requirements, but can include recommendations that may help a firm meet
9 the requirements of current good manufacturing processes (CGMPs) as defined by the U.S. Food
10 and Drug Administration (FDA).⁵

11
12 FDA Guidance regarding CGMP includes recommendations and precautions when manufacturing
13 ADIs to ensure that contamination by pathogenic agents does not occur. No guidance regarding
14 labeling of ADIs could be located. Although the FDA does have a database that provides
15 information on inactive ingredients present in FDA-approved drug products, its main purpose is to
16 aid industry in drug development; once an inactive ingredient is part of the formulation for an
17 approved drug product, it is no longer considered new and may require less extensive review when
18 used again. The database includes no information regarding the source of the ingredient.⁶

19
20 USP-NF general chapter <7> “Labeling” details the requirements for the labeling of active
21 ingredients in pharmaceutical products. No discussion of ingredient source is included. It is noted,
22 however, that many monographs have unique labeling requirements that should be used
23 consistently. USP-NF informational chapter <1091> “Labeling of Inactive Ingredients” states that
24 all ingredients should be disclosed for all medications. The information can be found on the
25 package or insert of a prescription drug and on the drug facts label on the outside of the box for
26 over-the-counter drugs. No requirement exists for a manufacturer to declare how an ingredient is
27 sourced. Additionally, the Code of Federal Regulations calls for all ingredients to be listed, but
28 inactive ingredients are exempt from provisions on misbranding, including some that relate to false
29 or misleading labeling.⁷

30
31 **CULTURAL CONSIDERATIONS**

32
33 Some religious groups avoid products from certain animals and many patients have strong religious
34 convictions and beliefs. Vegetarians do not consume foods either directly obtained or using
35 products from the slaughter of an animal. Vegans do not consume any foods originating from
36 animals.

37
38 Several investigators have surveyed worldwide religious leaders for their opinions regarding the
39 acceptability of certain medical products, both medications and surgical implants/dressings/mesh,
40 for their religions.^{1,8-11} The surveys generally focused on the six largest religions worldwide and
41 reported varied practices. Many Hindus and Sikhs do not approve of the use of bovine- or porcine-
42 derived products and also follow vegetarian diets. Many who practice Islam or Judaism do not
43 accept the use of porcine-derived products. No principle in Buddhism prohibits the use of animal-
44 derived medical products; however, many members of one of the two major branches follow a
45 vegetarian diet. Most Christians, other than those who follow vegetarian or vegan diets, do not
46 have restrictions. Although Jehovah’s Witnesses refuse blood transfusions, all other medical related
47 products and decisions are at the discretion of the patient and physician. Notably, leaders from all
48 surveyed religions stated that the use of animal-derived medical products would be accepted in the
49 absence of any other alternative or in emergency situations. In difficult situations, religious leaders
50 can also be contacted for guidance.

1 OTHER CONSIDERATIONS
2

3 Various communication practices for patient-directed medication information including readability,
4 container labeling (font, format, and organization), information content length, and supplementary
5 medication instructions have been described, but do not address ingredient lists and source.¹²
6

7 Reports of medication non-adherence or discontinuation because of ADI avoidance exist.¹³ Some
8 authors have suggested that when healthcare professionals listen to patients' cultural beliefs,
9 actively involve them in medication prescribing decisions, and take their views and preferences
10 into account, adherence is more likely.¹⁴
11

12 Nevertheless, ADI information is inconsistently reported, difficult to obtain, and sometimes
13 incorrect.^{2,15} Also noteworthy is the fact that excipients and inactive ingredients likely differ
14 between branded and generic forms of medications; therefore, knowledge of the ingredients in a
15 particular branded medication will not guarantee knowledge of generic versions. Some drugs,
16 especially those produced in gelatin capsules, may be available in alternative formulations that do
17 not contain ADIs. Literature discussing clinical decision support systems for physicians and drug
18 databases used by pharmacists has not addressed the issue of ADIs and the inclusion of relevant
19 ADI information. If the source of ADIs, or the fact that an ingredient is an ADI, were required
20 labeling for manufacturers, the potential would exist for this information to be included in the
21 datasets used by clinical decision support systems and drug databases downstream.
22

23 PROBLEM MEDICAL PRODUCTS
24

25 Both active and inactive pharmaceutical ingredients as well as implants, dressings, and mesh used
26 in surgery can contain ADIs. Some of the more common examples of these ADIs are included in
27 discussion below.
28

29 *Active Ingredients*
30

31 The following are examples of products that contain an active ingredient derived from an animal
32 source:

- 33 • Conjugated estrogens (Premarin) are derived from the urine of pregnant mares.¹⁶
- 34 • Low molecular weight heparin is porcine-derived.¹⁷
- 35 • Corticotropin is obtained from porcine pituitary gland.¹⁸
- 36 • Hyaluronidase is derived from crude extracts of ovine or bovine testicular tissue.¹⁹
- 37 • Pancreatin (also known as pancreatic enzymes, pancrelipase) is bovine derived.²⁰

38 The product information for these medications indicates that they are animal-derived. However, for
39 some, the information is difficult to locate, often only becoming obvious because of a statement in
40 the "allergy" or "contraindications" section (e.g., This medication is contraindicated in patients
41 with sensitivity to proteins of porcine origin.).
42

43 *Inactive Ingredients*
44

45 In a recent review, the use of ADIs in the 100 most commonly prescribed medications in primary
46 care in the United Kingdom found that 74 contained at least one of the three most common
47 excipient ADIs used – gelatin, lactose, and magnesium stearate.¹⁵ Of these 74 products, 42
48 provided no indication of the presence of an ADI, and 2 products incorrectly stated that no animal
49 content was contained in the product.¹⁵
50

1 Gelatin is a generic term for a mixture of purified protein fractions obtained by hydrolysis of
2 animal collagen obtained from bovine or porcine bone, or from bovine, porcine, or fish skin. It is
3 most frequently used in the capsules of medications. Due to the demand for gelatin-free
4 medication, the production of vegetarian capsules made from hypromellose has expanded, and the
5 use of bioreactors utilizing “cellular agriculture” to create purified proteins that are assembled into
6 collagen and then made into gelatin is becoming popular; but animal-derived gelatin is still used
7 commonly.^{2,21}

8
9 Lactose is a natural disaccharide present in the milk of most mammals and is traditionally extracted
10 from milk using bovine rennet. Some manufacturers now use a vegetarian process instead of
11 bovine rennet to extract lactose from bovine milk, but this has caused confusion about suitability
12 for those who avoid bovine products.¹⁵ Lactose is widely used as a filler and diluent in tablets and
13 capsules and is also used as a diluent in dry-powder inhalations, in the preparation of sugar-coating
14 solutions, and in some injections.^{2,15}

15
16 Stearic acid, utilized as magnesium stearate in products, is a fatty acid sourced from rendered
17 bovine, porcine, or ovine fat or produced from vegetable matter. It is primarily used as a lubricant
18 in capsule and tablet manufacture and improves the solubility of some medications. If the source of
19 the magnesium stearate is not indicated on a drug label, whether or not it is an ADI is unknown and
20 difficult to determine.²

21
22 *Vaccines*
23

24 Materials used in the production of some vaccines, e.g., excipients or nutritional supplements for
25 cell cultures, are ADIs. These include gelatin, trypsin (usually bovine sourced), and bovine serum
26 or albumin.²² Religious scholars distinguish between the use of ADIs in oral or non-oral
27 medications and have issued rulings or waivers that allow use of non-oral medications containing
28 ADIs, such as vaccines.² Despite this distinction, reports persist of concern with ADIs in
29 vaccines.¹⁵

30
31 *Surgical Sutures, Implants, Dressings, and Mesh*
32

33 The use of synthetic and biological products is widespread in surgeries, and the use of a biologic
34 product that is prohibited or is sacred in a surgical setting is a concern.^{8,10} Sutures used to close
35 wounds or surgical incisions can contain animal-derived ingredients. A recent study confirmed the
36 frequent use of ADIs, such as collagen membrane, collagen gel, fibrin glue, fibrinogen, aprotinin
37 and some types of chitosan culture media and scaffold, in various arthroscopy products.¹⁰ Allograft
38 and xenograft mesh products have also been cited as problematic for patients with issues related to
39 the use of ADIs.¹¹ Authors encourage surgeons to know the source of the products they use as well
40 as the basic requirements of their patient’s faith, possibly even gaining informed consent before the
41 use of animal-derived surgical implants.^{8,11}

42
43 CURRENT AMA POLICY
44

45 No AMA policy addresses this issue.

46
47 CONCLUSION

48
49 Several medication ingredients, both active and inactive, and surgical products contain ingredients
50 derived from animal sources. Patients may have strong religious convictions and cultural beliefs
51 leading them to object to using medical products with animal-derived ingredients.

1 It has been documented that physicians may have a hard time determining the origin of ingredients
2 because the information is inconsistently reported, difficult to obtain, and sometimes incorrect.
3 Many times, reading the list of ingredients of a medical product will not clarify if the product
4 contains any animal-derived ingredients or components. Additionally, the products can vary in
5 regard to ADIs based on the manufacturer, and between brand name and generic versions.
6

7 Because no requirement exists for a manufacturer to declare how an ingredient is sourced on label
8 information, this information is not present in clinical decision support systems for physicians and
9 drug databases. Including additional information, such as the presence of ADIs and their source, in
10 the ingredients lists on drug labels and in product information would be beneficial because this
11 information could then be included in information systems used by clinicians and would be more
12 accessible to patients.
13

14 RECOMMENDATION
15

16 The Board of Trustees recommends the following be adopted in lieu of Resolution 515-A-18, and
17 the remainder of the report be filed:
18

19 Animal-Derived Ingredients
20

21 Our AMA:
22

23 1. Urges the U.S. Food and Drug Administration to require manufacturers to include all
24 ingredients and components present in medical products on the product label, including
25 both active and inactive ingredients, and denote any derived from an animal source. (New
26 HOD Policy)
27

28 2. Encourages cultural awareness regarding patient preferences associated with medical
29 products containing active or inactive ingredients or components derived from animal
30 sources. (New HOD Policy)

Fiscal Note: Less than \$500

REFERENCES

1. Eriksson A, Burcharth J, Rosenberg J. Animal derived products may conflict with religious patients' beliefs. *BMC Medical Ethics*. 2013;14(1):48.
2. Implications of religious and cultural beliefs on selection of medicines. *Drug and Therapeutics Bulletin*. 2016;54(4):45-48.
3. Sattar SP, Ahmed MS, Madison J, et al. Patient and physician attitudes to using medications with religiously forbidden ingredients. *Ann Pharmacother*. 2004;38(11):1830-1835.
4. 21 U.S.C. ch. 9 § 301.
5. U.S. Food and Drug Administration. Current Good Manufacturing Practice (CGMP) Regulations. 2018; <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm090016.htm>. Accessed July 23, 2018.
6. U.S. Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products: Frequently Asked Questions. 2017; <https://www.fda.gov/drugs/informationondrugs/ucm080123.htm>. Accessed July 23, 2018.
7. 21 C.F.R. pt. 201
8. Easterbrook C, Maddern G. Porcine and bovine surgical products: Jewish, Muslim, and Hindu perspectives. *Arch Surg*. 2008;143(4):366-370; discussion 370.
9. Fitzpatrick SJ, Jordens CF, Kerridge IH, et al. Religious perspectives on the use of psychopharmaceuticals as an enhancement technology. *J Relig Health*. 2014;53(5):1440-1455.
10. Goyal D, Goyal A, Brittberg M. Consideration of religious sentiments while selecting a biological product for knee arthroscopy. *Knee Surg Sports Traumatol Arthrosc*. 2013;21(7):1577-1586.
11. Jenkins ED, Yip M, Melman L, Frisella MM, Matthews BD. Informed consent: cultural and religious issues associated with the use of allogeneic and xenogeneic mesh products. *J Am Coll Surg*. 2010;210(4):402-410.
12. Mullen RJ, Duhig J, Russell A, Scarazzini L, Lievano F, Wolf MS. Best-practices for the design and development of prescription medication information: A systematic review. *Patient Educ Couns*. 2018;101(8):1351-1367.
13. Sattar SP, Shakeel Ahmed M, Majeed F, Petty F. Inert medication ingredients causing nonadherence due to religious beliefs. *Ann Pharmacother*. 2004;38(4):621-624.
14. National Collaborating Centre for Primary C. National Institute for Health and Clinical Excellence: Guidance. *Medicines Adherence: Involving Patients in Decisions About Prescribed Medicines and Supporting Adherence*. London: Royal College of General Practitioners (UK); 2009.
15. Tatham KC, Patel KP. Suitability of common drugs for patients who avoid animal products. *BMJ : British Medical Journal*. 2014;348.
16. Pfizer Inc. Premarin Product Label. <http://labeling.pfizer.com/showlabeling.aspx?id=131>. Accessed July 26, 2018.
17. Amin A. Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees. *Pharmaceuticals*. 2011;4(11):1475-1487.
18. Acthar Gel Product Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022432s000lbl.pdf. Accessed July 26, 2018.
19. Dunn AL, Heavner JE, Racz G, Day M. Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management. *Expert Opin Biol Ther*. 2010;10(1):127-131.
20. Creon Product Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020725s000lbl.pdf. Accessed July 26, 2018.
21. Dance A. Engineering the animal out of animal products. *Nat Biotechnol*. 2017;35(8):704-707.
22. Grabenstein JD. What the world's religions teach, applied to vaccines and immune globulins. *Vaccine*. 2013;31(16):2011-2023.

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 901
(I-18)

Introduced by: Medical Student Section

Subject: Support for Preregistration in Biomedical Research

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, Current AMA policy calls for physicians to “report the results of research accurately,
2 including subsequent negative findings”, particularly when “the findings do not support the
3 research hypothesis”;¹ and

4
5 Whereas, There are hurdles to the publication of negative research findings because of
6 publication bias wherein journals are less likely to accept manuscripts reporting negative
7 findings;² and

8
9 Whereas, The AMA supports the reproducibility of research findings by advocating that scientific
10 research “employ study designs that will yield scientifically valid and significant data”;³ and

11
12 Whereas, There is a systemic lack of reproducibility among published biomedical research
13 studies⁴, as highlighted by a recent report finding that nearly 70% of researchers were unable to
14 reproduce another scientist’s results;^{4,5} and

15
16 Whereas, Preregistration of a research study is the act of committing to clearly defined research
17 questions and analytical plans prior to the observation of the research outcomes, usually
18 achieved by posting an analysis plan to an independent registry;⁶ and

19
20 Whereas, Establishing hypotheses prior to observation of outcomes has been associated with a
21 four-fold reduction in rates of reporting false positive findings, suggesting that preregistration
22 can increase replicability of research;⁷ and

23
24 Whereas, The proportion of large clinical trials reporting negative findings increased from 43%
25 to 92% after preregistration of clinical trials became mandatory in the United States, showing
26 that “preregistration is correlated with outcomes that suggest reduced publication or reporting
27 biases”;⁸ therefore be it

¹ AMA Code of Medical Ethics Opinion E-7.2.1 Principles for Disseminating Research Results

² Nosek BA, Ebersole CR, DeHaven AC, Mellor DT. The Preregistration Revolution. *Proceedings of the National Academy of Sciences*. 2018;115(11):2600-2606. doi:[10.1073/pnas.1708274114](https://doi.org/10.1073/pnas.1708274114); Franco A, Malhotra N, Simonovits G. Publication Bias in the Social Sciences: Unlocking the File Drawer. *Science*. 2014;345(6203):1502-1505.

³ AMA Code of Medical Ethics Opinion E-7.1.3 Study Design and Sampling

⁴ Ioannidis JPA. Why Most Published Research Findings Are False. *PLoS Medicine*. 2005;2(8):e124. doi:[10.1371/journal.pmed.0020124](https://doi.org/10.1371/journal.pmed.0020124); Begley CG, Ellis LM. Drug Development: Raise Standards for Preclinical Cancer Research. *Nature*. 2012;483(7391):531.

⁵ Baker M. 1,500 Scientists Lift the Lid on Reproducibility. *Nature*. 2016;533(7604):452-454.

⁶ Nosek BA, et al. The Preregistration Revolution.

⁷ Swaen GGMH, Teggeler O, van Amelsvoort LGPM. False Positive Outcomes and Design Characteristics in Occupational Cancer Epidemiological Studies. *International Journal of Epidemiology*. 2001;30(5):948-954.

⁸ Kaplan RM, Irvin VL. Likelihood of Null Effects of Large NHLBI Cancer Trials Has Increased Over Time. *PLoS One*. 2015;10(8):e0132382; Nosek BA, et al. The Preregistration Revolution.

1 RESOLVED, That our American Medical Association support preregistration in order to mitigate
2 publication bias and improve the reproducibility of biomedical research. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000.

Date Received: 09/21/18

RELEVANT AMA POLICY

E-7.1.3 Study Design & Sampling

To be ethically justifiable, biomedical and health research that involves human subjects must uphold fundamental principles of respect for persons, beneficence, and justice. These principles apply not only to the conduct of research, but equally to the selection of research topics and study design.

Well-designed, ethically sound research aligns with the goals of medicine, addresses questions relevant to the population among whom the study will be carried out, balances the potential for benefit against the potential for harm, employs study designs that will yield scientifically valid and significant data, and generates useful knowledge. For example, research to develop biological or chemical weapons is antithetical to the goals of the medical profession, whereas research to develop defenses against such weapons can be ethically justifiable.

Physicians who engage in biomedical or health research with human participants thus have an ethical obligation to ensure that any study with which they are involved:

- (a) Is consistent with the goals and fundamental values of the medical profession.
- (b) Addresses research question(s) that will contribute meaningfully to medical knowledge and practice.
- (c) Is scientifically well designed to yield valid data to answer the research question(s), including using appropriate population and sampling controls, clear and appropriate inclusion/exclusion criteria, a statistically sound plan for data collection and analysis, appropriate controls, and when applicable, criteria for discontinuing the study (stopping rules).
- (d) Minimizes risks to participants, including risks associated with recruitment and data collection activities, without compromising scientific integrity.
- (e) Provides mechanisms to safeguard confidentiality.
- (f) Does not disproportionately recruit participants from historically disadvantaged populations or populations whose ability to provide fully voluntary consent is compromised. Participants who otherwise meet inclusion/exclusion criteria should be recruited without regard to race, ethnicity, gender, or economic status.
- (g) Recruits participants who lack the capacity to give informed consent only when the study stands to benefit that class of participants and participants with capacity would not yield valid results. In this event, assent should be sought from the participant and consent should be obtained from the prospective participants legally authorized representative, in keeping with ethics guidance.
- (h) Has been reviewed and approved by appropriate oversight bodies.

[AMA Principles of Medical Ethics: I,II,III,V,VII](#)

Issued: 2016

E-7.2.1 Principles for Disseminating Research Results

Physicians have an ethical responsibility to learn from and contribute to the total store of scientific knowledge. When they engage in biomedical or health research, physicians have obligations as scientists, which include disseminating research findings. Prompt presentation to scientific peers and publication of research findings are foundational to good medical care and promote enhanced patient care, early evaluation of clinical innovations, and rapid dissemination of improved techniques.

To fulfill their ethical responsibilities with respect to sharing research findings for the ultimate benefit of patients, physicians should:

- (a) Advocate for timely and transparent dissemination of research data and findings. Physicians should not intentionally withhold information for reasons of personal gain.
- (b) Report the results of research accurately, including subsequent negative findings. This is particularly important where the findings do not support the research hypothesis.
- (c) Maintain a commitment to peer review.
- (d) Disclose sponsorship and conflicts of interest relating to the research, in keeping with ethics guidance.
- (e) Be responsible in their release of research results to the media, ensuring that any information the researcher provides is prompt and accurate and that informed consent to the release of information has

been obtained from research participants (or participants legally authorized representative when the participant lacks decision-making capacity) prior to releasing any identifiable information.

In rare circumstances, the potential for misuse of research results could affect the decision about when and whether to disseminate research findings. Physician-researchers should assess foreseeable ramifications of their research in an effort to balance the promise of benefit against potential harms from corrupt application. Only under rare circumstances should findings be withheld, and then only to the extent required to reasonably protect against misuse.

[AMA Principles of Medical Ethics: I,II,III,V,VII](#)

Issued: 2016

Food Additives H-150.998

Our AMA supports the passage of legislation that would amend the Food Additive Act to require evidence based upon scientifically reproducible studies of the association of food additives with an increased incidence of cancer in animals or humans at dosage levels related to the amounts calculated as normal daily consumption for humans before removal of an additive from the market.

Citation: (Sub. Res. 4, A-77; Reaffirmed: CLRPD Rep. C, A-89; Reaffirmed: Sunset Report, A-00; Modified: BOT Rep. 6, A-10)

Increasing Minority Participation in Clinical Research H-460.911

1. Our AMA advocates that:

- a. The Food and Drug Administration (FDA) conduct annual surveillance of clinical trials by gender, race, and ethnicity, including consideration of pediatric and elderly populations, to determine if proportionate representation of women and minorities is maintained in terms of enrollment and retention. This surveillance effort should be modeled after National Institute of Health guidelines on the inclusion of women and minority populations.
- b. The FDA have a page on its web site that details the prevalence of minorities and women in its clinical trials and its efforts to increase their enrollment and participation in this research; and
- c. Resources be provided to community level agencies that work with those minorities who are not proportionately represented in clinical trials to address issues of lack of access, distrust, and lack of patient awareness of the benefits of trials in their health care. These minorities include Hispanics, Asians/Pacific Islanders/Native Hawaiians, and Native Americans.

2. Our AMA recommends the following activities to the FDA in order to ensure proportionate representation of minorities in clinical trials:

- a. Increased fiscal support for community outreach programs; e.g., culturally relevant community education, community leaders' support, and listening to community's needs;
- b. Increased outreach to female physicians to encourage recruitment of female patients in clinical trials;
- c. Continued minority physician education on clinical trials, subject recruitment, subject safety, and possible expense reimbursements;
- d. Support for the involvement of minority physicians in the development of partnerships between minority communities and research institutions; and
- e. Fiscal support for minority recruitment efforts and increasing trial accessibility through transportation, child care, reimbursements, and location.

3. Our AMA advocates that specific results of outcomes in all clinical trials, both pre- and post-FDA approval, are to be determined for all subgroups of gender, race and ethnicity, including consideration of pediatric and elderly populations; and that these results are included in publication and/or freely distributed, whether or not subgroup differences exist.

BOT Rep. 4, A-08 Reaffirmed: CSAPH Rep. 01, A-18

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 902
(I-18)

Introduced by: Medical Student Section

Subject: Increasing Patient Access to Sexual Assault Nurse Examiners

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, One in 6 women and 1 in 33 men have experienced an attempted or completed rape
2 in their lifetime, and there were 323,450 reports of rape or sexual assault in the United States in
3 2016;^{1,2} and

4
5 Whereas, Hospital emergency departments (EDs) typically serve as the primary point of care for
6 survivors of sexual assault, accounting for approximately 65,000–90,000 emergency
7 department visits per year;³ and

8
9 Whereas, The medical forensic examination (MFE) consists of a full head-to-toe physical
10 examination focused on documenting a patient's physical injuries and procuring DNA evidence
11 to assist in the prosecution of a case;⁴ and

12
13 Whereas, Performing a MFE has been shown to increase prosecution rates, and patients who
14 have chosen to undergo the MFE may do so to gain closure and emotional healing from the
15 traumatic event;⁵ and

16
17 Whereas, While the MFE can be completed by a variety of healthcare providers including
18 emergency medicine (EM) physicians, nurses/nurse practitioners, and physician assistants, EM
19 physicians are the primary examiner performing these exams despite recommendations that
20 encourage the involvement of other providers;^{4,6} and

21
22 Whereas, The MFE takes on average two hours to perform, must be completed within 72 hours
23 of the assault, and a chain of custody must be maintained where the examiner cannot leave the
24 evidence unattended until it is sealed for storage or handed to an authorized law enforcement
25 agent;^{4,7} and

26
27 Whereas, EM physicians typically see 2.48 patients per hour, which makes it difficult to
28 effectively complete the MFE and maintain custody of the evidence alongside their clinical
29 responsibilities;^{4,8} and

¹ RAINN, "Victims of Sexual Violence: Statistics | RAINN," 2018, <https://www.rainn.org/statistics/victims-sexual-violence>.

² Rachel Morgan and Grace Kena, "Criminal Victimization, 2016," 2017, <https://www.bjs.gov/content/pub/pdf/cv16.pdf>.

³ Ashlesha Patel et al., "Assessing the Extent of Provision of Comprehensive Medical Care Management for Female Sexual Assault Patients in US Hospital Emergency Departments," *International Journal of Gynecology & Obstetrics* 123, no. 1 (October 2013): 24–28, <https://doi.org/10.1016/j.ijgo.2013.04.014>.

⁴ Kristin Littel, "A National Protocol for Sexual Assault Medical Forensic Examinations - Adults/Adolescents Second Edition," 2013, <https://www.ncjrs.gov/pdffiles1/ovw/241903.pdf>.

⁵ Janice Du Mont, Deborah White, and Margaret J. McGregor, "Investigating the Medical Forensic Examination from the Perspectives of Sexually Assaulted Women," *Social Science & Medicine* 68, no. 4 (February 1, 2009): 774–80, <https://doi.org/10.1016/J.SOCSCIMED.2008.11.010>.

⁶ Margaret K Sande et al., "Sexual Assault Training in Emergency Medicine Residencies: A Survey of Program Directors," *The Western Journal of Emergency Medicine* 14, no. 5 (September 2013): 461–66, <https://doi.org/10.5811/westjem.2013.2.12201>.

⁷ "What Is a Rape Kit? | RAINN," accessed April 11, 2018, <https://www.rainn.org/articles/rape-kit>.

⁸ Joseph Harrington, "Patient-Per-Hour Staffing Ratios Over the Last 5 Years of EDBA Surveys," ACEP Now, 2016, http://www.acepnow.com/article/emergency-department-benchmarking-alliance-releases-2014-data-on-staffing-physician-productivity/acep_0116_pg13b.

1 Whereas, There is currently no national consensus on EM resident education for sexual assault
2 examinations, leading to EM physicians who are undertrained to complete the MFE;⁹ and
3
4 Whereas, Sexual assault nurse examiners (SANE) are health care personnel specially trained
5 to perform the MFE and their involvement is associated with higher rates of survivors'
6 psychological recovery and offender prosecution due to better collection of forensic data;^{10,11}
7 and
8
9 Whereas, Although there are now over 600 SANE programs nationwide, many EDs lack access
10 to SANE personnel, especially in rural or smaller communities;^{12,13} and
11
12 Whereas, The United States Government Accountability Office released a study highlighting
13 "weak stakeholder support for examiners" as one of the main reasons for poor availability of
14 SANE personnel;¹⁴ and
15
16 Whereas, The American College of Emergency Physicians, the International Association of
17 Forensic Nurses, and the Department of Justice all recommend that the MFE be performed by
18 specially trained medical personnel such as a SANE, and the Police Foundation in Texas found
19 that there is "reluctance by nurses, hospital administrators and criminal justice officials to [have]
20 non-SANEs conduct medical forensic exams";^{14,15} and
21
22 Whereas, Expanding the SANE program nationwide may decrease the burden on ED
23 physicians and provide better care to sexual assault survivors;^{4,15} therefore be it
24
25 RESOLVED, That our American Medical Association advocate for increased patient access to
26 sexual assault nurse examiners in the emergency department. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000.

Date Received: 09/21/18

RELEVANT AMA POLICY

Sexual Assault Survivors H-80.999

1. Our AMA supports the preparation and dissemination of information and best practices intended to maintain and improve the skills needed by all practicing physicians involved in providing care to sexual assault survivors.
2. Our AMA advocates for the legal protection of sexual assault survivors rights and work with state medical societies to ensure that each state implements these rights, which include but are not limited to, the right to: (A) receive a medical forensic examination free of charge, which includes but is not limited to HIV/STD testing and treatment, pregnancy testing, treatment of injuries, and collection of forensic evidence; (B) preservation of a sexual assault evidence collection kit for at least the maximum applicable statute of limitation; (C) notification of any intended disposal of a sexual assault evidence kit with the opportunity to be granted further preservation; (D) be informed of these rights and the policies governing the sexual assault evidence kit; and (E) access to emergency contraception information and treatment for pregnancy prevention.

⁹ Margaret K Sande et al., "Sexual Assault Training in Emergency Medicine Residencies: A Survey of Program Directors," *The Western Journal of Emergency Medicine* 14, no. 5 (September 2013): 461–66, <https://doi.org/10.5811/westjem.2013.2.12201>.

¹⁰ Megan R. Greeson and Rebecca Campbell, "Coordinated Community Efforts to Respond to Sexual Assault," *Journal of Interpersonal Violence* 30, no. 14 (September 13, 2015): 2470–87, <https://doi.org/10.1177/0886260514553119>.

¹¹ Rebecca Campbell, Debra Patterson, and Lauren F. Lichty, "The Effectiveness of Sexual Assault Nurse Examiner (SANE) Programs," *Trauma, Violence, & Abuse* 6, no. 4 (October 29, 2005): 313–29, <https://doi.org/10.1177/1524838005280328>.

¹² "International Association of Forensic Nurses," 2018, accessed March 28, 2018, <http://www.forensicnurses.org/>.

¹³ Liv Osby, "SC Has a Shortage of Nurses for Rape Victims," The State, 2017, <http://www.thestate.com/news/local/article162841233.html>.

¹⁴ Katherine M. Iritani, "Information on Training, Funding, and the Availability of Forensic Examiners," *United States Government Accountability Office* 16, no. 334 (2016), <https://www.gao.gov/assets/680/675879.pdf>.

¹⁵ Robert C Davis et al., "IMPACT OF SB1191 ON ACCESSIBILITY OF SEXUAL ASSAULT FORENSIC EXAMS IN TEXAS," 2017, http://www.policefoundation.org/wp-content/uploads/2017/02/PF_Impact-of-SB1191-on-Accessibility-of-Sexual-Assault-Forensic-Exams-in-Texas_2.7.17.pdf.

3. Our AMA will collaborate with relevant stakeholders to develop recommendations for implementing best practices in the treatment of sexual assault survivors, including through engagement with the joint working group established for this purpose under the Survivor's Bill of Rights Act of 2016.

Citation: Sub. Res. 101, A-80; Reaffirmed: CLRPD Rep. B, I-90; Reaffirmed: Sunset Report, I-00; Reaffirmed: CSAPH Rep. 1, A-10; Modified: Res. 202, I-17

Sexual Assault Survivor Services H-80.998

Our AMA supports the function and efficacy of sexual assault survivor services, supports state adoption of the sexual assault survivor rights established in the Survivors' Bill of Rights Act of 2016, encourages sexual assault crisis centers to continue working with local police to help sexual assault survivors, and encourages physicians to support the option of having a counselor present while the sexual assault survivor is receiving medical care.

Citation: Res. 56, A-83; Reaffirmed: CLRPD Rep. 1, I-93; Reaffirmed: CSA Rep. 8, A-05; Reaffirmed: CSAPH Rep. 1, A-15; Modified: Res. 202, I-17

Access to Emergency Contraception H-75.985

It is the policy of our AMA: (1) that physicians and other health care professionals should be encouraged to play a more active role in providing education about emergency contraception, including access and informed consent issues, by discussing it as part of routine family planning and contraceptive counseling; (2) to enhance efforts to expand access to emergency contraception, including making emergency contraception pills more readily available through pharmacies, hospitals, clinics, emergency rooms, acute care centers, and physicians' offices; (3) to recognize that information about emergency contraception is part of the comprehensive information to be provided as part of the emergency treatment of sexual assault victims; (4) to support educational programs for physicians and patients regarding treatment options for the emergency treatment of sexual assault victims, including information about emergency contraception; and (5) to encourage writing advance prescriptions for these pills as requested by their patients until the pills are available over-the-counter.

Citation: (CMS Rep. 1, I-00; Appended: Res. 408, A-02; Modified: Res. 443, A-04; Reaffirmed: CSAPH Rep. 1, A-14)

HIV, Sexual Assault, and Violence H-20.900

Our AMA believes that HIV testing should be offered to all victims of sexual assault, that these victims should be encouraged to be retested in six months if the initial test is negative, and that strict confidentiality of test results be maintained.

Citation: (CSA Rep. 4, A-03; Modified: CSAPH Rep. 1, A-13)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 903
(I-18)

Introduced by: Medical Student Section
Subject: Regulating Front-of-Package Labels on Food Products
Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, Many front-of-package (FOP) labels on food products feature nutrient claims that
2 suggest or imply that a food has certain nutritional properties related to its content of
3 energy, proteins, fats, carbohydrates, dietary fiber, vitamins, and/or minerals; and
4
5 Whereas, FOP labels attract attention, thereby causing consumers to spend less time reading
6 the nutrition facts on the back and side panel of food products^{1,2}; and
7
8 Whereas, Research demonstrates that consumers will exhibit a preference for a product
9 with a FOP nutrient claim regardless of its qualitative value³; and
10
11 Whereas, Studies show that children perceive food products with nutrient claims on their FOP
12 label as healthier⁴; and
13
14 Whereas, Studies of responses to nutrition-related claims in food advertising have found
15 that consumers over-generalize a product's healthfulness based on narrower claims^{5,6,7,8};
16 and
17
18 Whereas, Many front-of-package labels (e.g. "Whole Grain" on sugary cereals and "Good
19 Source of Vitamins and Minerals" on toaster pastries) are placed on products that contain high
20 amounts of added sugar,⁹ meaning they do not comply with the 2015-2020 U.S. Dietary
21 Guidelines' recommendation that food products contain no more than 10% added sugars by
22 calorie value; and

¹ Bix, L., Sundar, R. P., Bello, N. M., Peltier, C., Weatherspoon, L. J., & Becker, M. W. (2015). To See or Not to See: Do Front of Pack Nutrition Labels Affect Attention to Overall Nutrition Information? *Plos One*, 10(10). doi:10.1371/journal.pone.0139732

² Becker, M. W., Sundar, R. P., Bello, N., Alzahabi, R., Weatherspoon, L., & Bix, L. (2016). Assessing attentional prioritization of front-of-pack nutrition labels using change detection. *Applied Ergonomics*, 54, 90-99. doi:10.1016/j.apergo.2015.11.014

³ Hamlin, R. P., Mcneill, L. S., & Moore, V. (2014). The impact of front-of-pack nutrition labels on consumer product evaluation and choice: An experimental study. *Public Health Nutrition*, 18(12), 2126-2134. doi:10.1017/s1368980014002997

⁴ Nutrition Claims Influence Health Perceptions and Taste Preferences in Fourth- and Fifth-Grade Children. (2012, September 23). Retrieved April 5, 2018, from <https://www.sciencedirect.com/science/article/pii/S1499404612003958>

⁵ Andrews, J. C., R. G. Netemeyer, and S. Burton. 1998. Consumer generalization of nutrient content claims in advertising. *Journal of Marketing* 62:62-75.

⁶ Kozup, J., E. Creyer, and S. Burton. 2003. Making healthful food choices: The influence of health claims and nutrition information on consumers' evaluations of packaged food products and restaurant menu items. *Journal of Marketing* 67:19-34.

⁷ Gorton, D., C. N. Mhurchu, D. Bramley, and R. Dixon. 2010. Interpretation of two nutrition content claims: A New Zealand survey. *Australian and New Zealand Journal of Public Health* 34:57-62.

⁸ Labiner-Wolfe, J., C. T. J. Lin, and L. Verrill. 2010. Effect of low-carbohydrate claims on consumer perceptions about food products' healthfulness and helpfulness for weight management. *Journal of Nutrition Education and Behavior* 42:315-320.

⁹ Ollberding, N. J., Wolf, R. L., & Contento, I. (2010). Food label use and its relation to dietary intake among US adults. *Journal of the American Dietetic Association*, 110(8), 1233-1237.

1 Whereas, Evidence shows that individuals who consume diets high in refined carbohydrates are
2 at a greater risk of becoming obese¹⁰, developing diabetes¹¹, and dying from a cardiovascular
3 event¹²; and
4
5 Whereas, The Food and Drug Administration (FDA) regulates front-of-package claims by
6 enforcing qualifying criteria that food products must meet for use of each individual nutrient
7 claim¹³; and
8
9 Whereas, The FDA has no requirement that food products labeled with nutrient claims that can
10 be generalized to imply healthfulness adhere to specific macronutrient limits; and
11
12 Whereas, Studies show that negative cues in the form of warning labels are demonstrated to
13 have a greater impact on consumer food choices than positive health claims^{14,15,16}; and
14
15 Whereas, Standardized warning labels have been mandated in Chile on food products high in
16 sugar, salt, fat, and calories since 2016¹⁷; and
17
18 Whereas, To avoid having to add warning labels to their products, food companies in Chile have
19 reformulated over 1,500 food products to be lower in sugar, salt, fat, and calories¹⁸; and
20
21 Whereas, Chilean consumers purchase more of the foods without warning labels than they did
22 before implementation of the warning labels^{19,20}; and
23
24 Whereas, Our AMA and AMA-MSS have established support for consumer-level interventions
25 and education about the effects of excessive dietary sugars (H-150.960, H-150.974,
26 H-150.935, H-150.945, D-150.975, D-150.987); and
27
28 Whereas, Our AMA and AMA-MSS have established support for the use of warning labels and
29 plain packaging on sugar-sweetened beverages (H-150.927); therefore be it

¹⁰ Cantoral, A., Téllez-Rojo, M. M., Ettinger, A. S., Hu, H., Hernández-Ávila, M., & Peterson, K. (2015). Early introduction and cumulative consumption of sugar-sweetened beverages during the pre-school period and risk of obesity at 8-14 years of age. *Pediatric Obesity*, 11(1), 68-74. doi:10.1111/jipo.12023

¹¹ Gross, L. S., Li, L., Ford, E. S., & Liu, S. (2004). Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: An ecologic assessment. *The American Journal of Clinical Nutrition*, 79(5), 774-779. doi:10.1093/ajcn/79.5.774

¹² Yang, Q., Zhang, Z., Gregg, E. W., Flanders, W. D., Merritt, R., & Hu, F. B. (2014). Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults. *JAMA Internal Medicine*, 174(4), 516. doi:10.1001/jamainternmed.2013.13563

¹³ Subpart D—Specific Requirements for Nutrient Content Claims, 58 FR 2413 (1993); 58 FR 17343 (1993), as amended at 58 FR § 44033 (1993); 62 FR § 40598 (1997); 63 FR § 26718 (1998); 63 FR § 40024 (1998); 67 FR § 9585 (2002); 69 FR § 16481 (2004).

¹⁴ Arrúa, A., Machín, L., Curutchet, M. R., Martínez, J., Antúnez, L., Alcaire, F., . . . Ares, G. (2017). Warnings as a direct front-of-pack nutrition labelling scheme: Comparison with the Guideline Daily Amount and traffic-light systems. *Public Health Nutrition*, 20(13), 2308-2317. doi:10.1017/s1368980017000866

¹⁵ Bolland, T., Maubach, N., Walker, N., & Mhurchu, C. N. (2016). Effects of plain packaging, warning labels, and taxes on young people's predicted sugar-sweetened beverage preferences: An experimental study. *International Journal of Behavioral Nutrition and Physical Activity*, 13(1). doi:10.1186/s12966-016-0421-7

¹⁶ Arrúa, A., Curutchet, M. R., Rey, N., Barreto, P., Golovchenko, N., Sellanes, A., . . . Ares, G. (2017). Impact of front-of-pack nutrition information and label design on childrens choice of two snack foods: Comparison of warnings and the traffic-light system. *Appetite*, 116, 139-146. doi:10.1016/j.appet.2017.04.012

¹⁷ Carreño, I. (2015). Chile's Black STOP Sign for Foods High in Fat, Salt or Sugar. *European Journal of Risk Regulation*, 6(04), 622-628. doi:10.1017/s1867299x0000516x

¹⁸ Ares, G., Aschemann-Witzel, J., Curutchet, M. R., Antúnez, L., Machín, L., Vidal, L., & Giménez, A. (2018). Product reformulation in the context of nutritional warning labels: Exploration of consumer preferences towards food concepts in three food categories. *Food Research International*, 107, 669-674. doi:10.1016/j.foodres.2018.03.021

¹⁹ Ares, G., Aschemann-Witzel, J., Curutchet, M. R., Antúnez, L., Machín, L., Vidal, L., & Giménez, A. (2018). Product reformulation in the context of nutritional warning labels: Exploration of consumer preferences towards food concepts in three food categories. *Food Research International*, 107, 669-674. doi:10.1016/j.foodres.2018.03.021

²⁰ Arrúa, A., Curutchet, M. R., Rey, N., Barreto, P., Golovchenko, N., Sellanes, A., . . . Ares, G. (2017). Impact of front-of-pack nutrition information and label design on childrens choice of two snack foods: Comparison of warnings and the traffic-light system. *Appetite*, 116, 139-146. doi:10.1016/j.appet.2017.04.012

1 RESOLVED, That our American Medical Association support additional U.S. Food and Drug
2 Administration criteria that limit the amount of added sugar a food product can contain if it
3 carries any front-of-package label advertising nutritional or health benefits (New HOD Policy);
4 and be it further
5
6 RESOLVED, That our AMA support the use of front-of-package warning labels on foods that
7 contain excess added sugar. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000.

Date Received: 09/24/18

RELEVANT AMA POLICY

Nutrition Labeling and Nutritionally Improved Menu Offerings in Fast-Food and Other Chain Restaurants H-150.945

Our AMA:

1. supports federal, state, and local policies to require fast-food and other chain restaurants with 10 or more units (smaller, neighborhood restaurants could be exempt) to provide consumers with nutrition information on menus and menu boards;
2. recommends that nutrition information in fast-food and other chain restaurants include calorie, fat, saturated fat and trans fat, and sodium labeling on printed menus, and, at a minimum, calories on menu boards, since they have limited space, and that all nutrition information be conspicuous and easily legible;
3. urges federal, state, and local health agencies, health organizations, and physicians and other health professionals to educate people how to use the nutrition information provided in restaurants to make healthier food choices for themselves and their families; and
4. urges restaurants to improve the nutritional quality of their menu offerings--for example, by reducing caloric content; offering smaller portions; offering more fruits, vegetables, and whole-grain items; using less sodium; using cooking fats lower in saturated and trans fats; and using less added sugars/sweeteners.

Citation: (Res. 419, A-07; Reaffirmed in lieu of Res. 413, A-09, Res. 416, A-09 and Res. 418, A-09)

Encouraging Healthy Eating Behaviors in Children Through Corporate Responsibility H-150.935

Our AMA: 1) supports and encourages corporate social responsibility in the use of marketing incentives that promote healthy childhood behaviors, including the consumption of healthy food in accordance with federal guidelines and recommendations; and 2) encourages fast food restaurants to establish competitive pricing between less healthy and more healthy food choices in children's meals.

Citation: (Sub. Res. 402, A-11; Reaffirmation A-12; Reaffirmed in lieu of Res. 435, A-12)

Support for Uniform, Evidence-Based Nutritional Rating System H-150.936

1. Our AMA supports the adoption and implementation of a uniform, nutritional food rating system in the US that meets, at a minimum, the following criteria: is evidence-based; has been developed without conflict of interest or food industry influence and with the primary goal being the advancement of public health; is capable of being comprehensive in scope, and potentially applicable to nearly all foods; allows for relative comparisons of many different foods; demonstrates the potential to positively influence consumers' purchasing habits; provides a rating scale that is simple, highly visible, and easy-to-understand and used by consumers at point of purchase; and is adaptable to aid in overall nutritional decision making.
2. Our AMA will advocate to the federal government - including responding to the Food and Drug Administration call for comments on use of front-of-package nutrition labeling and on shelf tags in retail stores - and in other national forums for the adoption of a uniform, evidence-based nutrition rating system that meets the above-referenced criteria.

Citation: (Res. 424, A-10)

Support for Nutrition Label Revision and FDA Review of Added Sugars D-150.974

1. Our AMA will issue a statement of support for the newly proposed nutrition labeling by the Food and Drug Administration (FDA) during the public comment period.
2. Our AMA will recommend that the FDA further establish a recommended daily value (%DV) for the new added

sugars listing on the revised nutrition labels based on previous recommendations from the WHO and AHA).

3. Our AMA will encourage further research into studies of sugars as addictive through epidemiological, observational, and clinical studies in humans.

Citation: (Res. 422, A-14)

Increasing Awareness of Nutrition Information and Ingredient Lists H-150.948

Our AMA supports federal legislation or rules requiring restaurants, retail food establishments, and vending machine operators that have menu items common to multiple locations, as well as all school and workplace cafeterias, especially those located in health care facilities, to have available for public viewing ingredient lists, nutritional information, and standard nutrition labels for all menu items.

Citation: (Sub. Res. 411, A-04; Reaffirmation A-07; Reaffirmed in lieu of Res. 413, A-09, Res. 416, A-09 and Res. 418, A-09; Modified: BOT Rep. 1, A-14)

Strategies to Reduce the Consumption of Beverages with Added Sweeteners H-150.927

Our AMA: (1) acknowledges the adverse health impacts of sugar-sweetened beverage (SSB) consumption, and support evidence-based strategies to reduce the consumption of SSBs, including but not limited to, excise taxes on SSBs, removing options to purchase SSBs in primary and secondary schools, the use of warning labels to inform consumers about the health consequences of SSB consumption, and the use of plain packaging; (2) encourages continued research into strategies that may be effective in limiting SSB consumption, such as controlling portion sizes; limiting options to purchase or access SSBs in early childcare settings, workplaces, and public venues; restrictions on marketing SSBs to children; and changes to the agricultural subsidies system; (3) encourages hospitals and medical facilities to offer healthier beverages, such as water, unflavored milk, coffee, and unsweetened tea, for purchase in place of SSBs and apply calorie counts for beverages in vending machines to be visible next to the price; and (4) encourages physicians to (a) counsel their patients about the health consequences of SSB consumption and replacing SSBs with healthier beverage choices, as recommended by professional society clinical guidelines; and (b) work with local school districts to promote healthy beverage choices for students.

Citation: CSAPH Rep. 03, A-17;

Promotion of Healthy Lifestyles I: Reducing the Population Burden of Cardiovascular Disease by Reducing Sodium Intake H-150.929

Our AMA will:

(1) Call for a step-wise, minimum 50% reduction in sodium in processed foods, fast food products, and restaurant meals to be achieved over the next decade. Food manufacturers and restaurants should review their product lines and reduce sodium levels to the greatest extent possible (without increasing levels of other unhealthy ingredients). Gradual but steady reductions over several years may be the most effective way to minimize sodium levels.

(2) To assist in achieving the Healthy People 2010 goal for sodium consumption, will work with the FDA, the National Heart Lung Blood Institute, the Centers for Disease Control and Prevention, the American Heart Association, and other interested partners to educate consumers about the benefits of long-term, moderate reductions in sodium intake.

(3) Recommend that the FDA consider all options to promote reductions in the sodium content of processed foods.

Citation: CSAPH Rep. 01, A-16

Obesity as a Major Health Concern H-440.902

The AMA: (1) recognizes obesity in children and adults as a major public health problem; (2) will study the medical, psychological and socioeconomic issues associated with obesity, including reimbursement for evaluation and management of patients with obesity; (3) will work with other professional medical organizations, and other public and private organizations to develop evidence-based recommendations regarding education, prevention, and treatment of obesity; (4) recognizes that racial and ethnic disparities exist in the prevalence of obesity and diet-related diseases such as coronary heart disease, cancer, stroke, and diabetes and recommends that physicians use culturally responsive care to improve the treatment and management of obesity and diet-related diseases in minority populations; and (5) supports the use of cultural and socioeconomic considerations in all nutritional and dietary research and guidelines in order to treat patients affected by obesity.

Citation: Res. 423, A-98; Reaffirmed and Appended: BOT Rep. 6, A-04; Reaffirmation A-10; Reaffirmed in lieu of Res. 434, A-12; Reaffirmation A-13; Modified: Res. 402, A-17

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 904
(I-18)

Introduced by: Medical Student Section

Subject: Support for Continued 9-1-1 Modernization and the National Implementation of Text-to-911 Service

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, The current 9-1-1 system is primarily built upon an infrastructure that does not
2 uniformly support modern communications technologies including texting, geolocation, and
3 images;^{1, 2} and
4

5 Whereas, Current 9-1-1 infrastructure has continuously been shown to be vulnerable to
6 preventable outages and cyberattacks, which have already temporarily left thousands without
7 access to emergency services;^{3, 4, 5} and
8

9 Whereas, The Federal Communications Commission (FCC) has already recommended that
10 Congress increase federal incentives to boost state and local 9-1-1 modernization efforts;⁶ and
11

12 Whereas, Internet protocol (IP)- based communication technologies allow the transmission of
13 data over the internet, allowing for increased information (such as text and geolocation) to be
14 obtained by the receiver compared to old circuit-switch communication;⁷ and
15

16 Whereas, Congress has failed to nationally incorporate IP based technology into existing 9-1-1
17 infrastructure, which may lead to inaccurate caller location accuracy on calls over wireline in
18 multiple situations;⁸ and
19

20 Whereas, 95% of Americans own at least one cellphone, 77% own at least one smartphone,
21 and over 70% of all 9-1-1 calls are made from cellphones and other handheld devices;^{9, 10} and
22

23 Whereas, While the IP-based geolocation accuracy of handheld devices averages about 4.9
24 meters, current U.S. standards merely mandate that 67% of 9-1-1 calls are accurate within
25 range of 50 meters, a standard that has not been updated since 2012;^{11, 12} and

¹ Federal Communications Commission. 2013. Pursuant to the Next Generation 911 Advancement Act of 2012 (Pub. L. No. 112-96 (2012)). Legal and Regulatory Framework for Next Generation 911 Services Report to Congress and Recommendations. Section 1.

² Next Generation 9-1-1 Advancement Act of 2011, 47 U.S.C §158. (2012)

³ Public Safety and Homeland Security Bureau. Federal Communications Commission. 2013. Impact of the June 2012 Derecho on Communications Networks and Services: Report and Recommendations. Sections 1, 7.4, & 8.

⁴ Public Safety and Homeland Security Bureau. Federal Communications Commission. 2014. April 2014 Multistate 911 Outage: Cause and Impact. Sections 1, & 4.2.

⁵ Simpson, D. (2016, February 17). Creating a Culture of Cybersecurity in America's 911 Call Centers. Retrieved March 28, 2018, from <https://www.fcc.gov/news-events/blog/2016/01/28/creating-culture-cybersecurity-americas-911-call-centers>

⁶ Federal Communications Commission. 2013. Pursuant to the Next Generation 911 Advancement Act of 2012 (Pub. L. No. 112-96 (2012)). Legal and Regulatory Framework for Next Generation 911 Services Report to Congress and Recommendations. Section 4.1.1.2

⁷ Federal Communications Commission. 2013. Pursuant to the Next Generation 911 Advancement Act of 2012 (Pub. L. No. 112-96 (2012)). Legal and Regulatory Framework for Next Generation 911 Services Report to Congress and Recommendations. Section 3.1.2.

⁸ Federal Communications Commission. 2017. Inquiry Concerning 911 Access, Routing, and Location in Enterprise Communications Systems: Notice of Inquiry – PS Docket No. 17-239, Sections 1 & 2.

⁹ Mobile Fact Sheet. Pew Research Center. (2018, February 05). Retrieved March 28, 2018, from <http://www.pewinternet.org/fact-sheet/mobile/>

¹⁰ Federal Communications Commission. 2015. Consumer Guide: 911 Wireless Services. Available at <https://transition.fcc.gov/cgb/consumerfacts/wireless911src.pdf>

¹¹ 911 service, 47 C.F.R. § 20.18(h) (2012).

¹² GPS Accuracy. (2017, December 5). Retrieved March 25, 2018, from <https://www.gps.gov/systems/gps/performance/accuracy/>

1 Whereas, Increased 9-1-1 response times, due to factors such as imprecise call tracking, can
2 lead to increased morbidity in cardiac arrest;¹³ and
3
4 Whereas, The Americans with Disabilities Act of 1990 mandates that 9-1-1 services need only
5 receive message-based communication from teletypewriters (TTYs), devices which are distinct
6 and may be incompatible with modern mobile and smartphones;^{14, 15} and
7
8 Whereas, Approximately 50 million Americans have hearing disabilities, and 7.5 million
9 Americans have difficulty vocalizing words;^{16, 17} and
10
11 Whereas, The FCC found a majority of those with hearing and speech disabilities have
12 discarded their TTYs in favor of mobile plans with SMS services, leaving millions with these
13 disabilities at risk of not being able to effectively communicate with 9-1-1 operators;¹⁵ and
14
15 Whereas, Nationally, 9-1-1 call centers are not mandated to accept SMS messages (text-to-
16 911), meaning that a citizen's locale may dictate the amount of emergency services they have
17 access to;¹⁸ and
18
19 Whereas, The National Association of the Deaf (NAD) and the Hearing Loss Association of
20 America (HLAA) both acknowledge that the existing 9-1-1 infrastructure limits the ability of those
21 with deafness or hearing loss to contact emergency services;^{19, 20} and
22
23 Whereas, The NAD and HLAA both support continued modernization of 9-1-1 services,
24 including the continued implementation of text-to-911;^{19, 20} and
25
26 Whereas, Our AMA has adopted policy encouraging guidelines that protect against the
27 reallocation of 9-1-1 funding to unrelated programs (H-440.822), but does not currently
28 encourage the continued modernization of 9-1-1 services; therefore be it
29
30 RESOLVED, That our American Medical Association support the funding of federal grant
31 programs for the modernization of the 9-1-1 infrastructure, including incorporation of text to 911
32 technology. (New HOD Policy)

Fiscal note: Minimal - less than \$1,000.

Date Received: 09/24/18

RELEVANT AMA POLICY

Accountability of 911 Emergency Services Funding H-440.822

Our AMA encourages federal guidelines and state legislation that protects against reallocation of 911 funding to unrelated services.

Citation: Res. 220, A-17

¹³ Emergency medical services response to cardiac arrest. (2015). In R. Graham, M. McCoy & A. Schultz (Eds.), *Strategies to improve cardiac arrest survival: A time to act.* (pp. 190-192). National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001: National Academies Press. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK321505/>

¹⁴ Americans With Disabilities Act of 1990, Pub. L. No. 101-336, § IV (2012)

¹⁵ Federal Communications Commission. 2013. Pursuant to the Next Generation 911 Advancement Act of 2012 (Pub. L. No. 112-96 (2012)). Legal and Regulatory Framework for Next Generation 911 Services Report to Congress and Recommendations. Section 4.1.6.1.

¹⁶ Statistics on Voice, Speech, and Language. National Institute on Deafness and Other Communication Disorders. (2016, July 11). Retrieved March 28, 2018, from <https://www.nidcd.nih.gov/health/statistics/statistics-voice-speech-and-language>

¹⁷ Blackwell DL, Lucas JW, Clarke TC. Summary health statistics for U.S. adults: National Health Interview Survey, 2012. National Center for Health Statistics. Vital Health Stat 10(260). 2014.

¹⁸ Federal Communications Commission. 2017. Consumer Guide: Text-to-911: What You Need to Know. Available at <https://transition.fcc.gov/cgb/consumerfacts/text-to-911-consumer-guide.pdf>

¹⁹ National Association of the Deaf. (2018). Next generation 9-1-1 emergency services. Retrieved from <https://www.nad.org/resources/emergency-preparedness/next-generation-9-1-1-emergency-services/>

²⁰ Hearing Loss Association of America. (2018). 911. Retrieved from <http://www.hearingloss.org/content/911>

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 905
(I-18)

Introduced by: Medical Student Section

Subject: Support Offering HIV Post Exposure Prophylaxis to All Survivors of Sexual Assault

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, 19.3% of women and 1.7% of men in the United States report being raped during their
2 lifetime, and 1.8 per 1000 children have been sexually abused;¹ and
3
4 Whereas, The Centers for Disease Control and Prevention (CDC) estimates the risk of
5 contracting HIV from a known HIV-positive person through consensual vaginal intercourse at
6 0.1%–0.2% and anal intercourse at 0.5%–3%, and this risk may increase during sexual assault
7 due to injuries sustained by the individual;^{2,3} and
8
9 Whereas, Post-Exposure Prophylaxis (PEP) is antiretroviral medication (ART) taken within 72
10 hours of HIV exposure to prevent infection, and is extremely effective at preventing
11 seroconversion after HIV exposure;^{4,5,6,7,8,9,10} and
12
13 Whereas, Current CDC guidelines indicate that persons with nonoccupational exposure to HIV
14 should be offered PEP within 72 hours even if the HIV status of the exposer is unknown;^{11,12}
15 and

¹ Arlene C. Seña et al., "Sexual Assault and Sexually Transmitted Infections in Adults, Adolescents, and Children," *Clinical Infectious Diseases* 61, no. suppl 8 (December 15, 2015): S856–64, doi:10.1093/cid/civ786.

² Jessica E Draughon, "Sexual Assault Injuries and Increased Risk of HIV Transmission," *Advanced Emergency Nursing Journal* 34, no. 1 (2012): 82–87, doi:10.1097/TME.0b013e3182439e1a.

³ Jennifer F Klot et al., "Greentree White Paper: Sexual Violence, Genitoanal Injury, and HIV: Priorities for Research, Policy, and Practice," *AIDS Research and Human Retroviruses* 28, no. 11 (November 2012): 1379–88, doi:10.1089/AID.2012.0273.

⁴ Réjean Thomas et al., "Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort," ed. Cristian Apetrei, *PLOS ONE* 10, no. 11 (November 11, 2015): e0142534, doi:10.1371/journal.pone.0142534.

⁵ M. E. Roland et al., "Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV," *Clinical Infectious Diseases* 41, no. 10 (November 15, 2005): 1507–13, doi:10.1086/497268.

⁶ Sarah J. McDougal et al., "Non-Occupational Post-Exposure Prophylaxis for HIV: 10-Year Retrospective Analysis in Seattle, Washington," ed. Roger Le Grand, *PLOS ONE* 9, no. 8 (August 20, 2014): e105030, doi:10.1371/journal.pone.0105030.

⁷ F Tissot et al., "Nonoccupational HIV Post-Exposure Prophylaxis: A 10-Year Retrospective Analysis," *HIV Medicine* 11, no. 9 (October 1, 2010): 584–92, doi:10.1111/j.1468-1293.2010.00826.x.

⁸ Trine Gulholm et al., "Non-Occupational HIV Post-Exposure Prophylaxis at a Sydney Metropolitan Sexual Health Clinic," *Sexual Health* 10, no. 5 (November 2013): 438, doi:10.1071/SH13018.

⁹ Cadi Irvine et al., "Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-Analysis of Nonhuman Primate Studies," *Clinical Infectious Diseases* 60, no. suppl_3 (June 1, 2015): S165–69, doi:10.1093/cid/civ069.

¹⁰ U.S. Department of Health & Human Services, "Post-Exposure Prophylaxis," 2015, <https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/post-exposure-prophylaxis>.

¹¹ Kenneth L. Dominguez et al., "Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016," 2016, <https://stacks.cdc.gov/view/cdc/38856>.

¹² AIDS Institute Clinical Guidelines, "PEP for Victims of Sexual Assault Guideline" (Baltimore, MD: HIV Clinical Resource, 2016), <https://www.hivguidelines.org/pep-for-hiv-prevention/after-sexual-assault/>.

1 Whereas, Hospital emergency departments (EDs) typically serve as the primary point of care for
2 survivors of sexual assault, accounting for approximately 65,000–90,000 emergency
3 department visits per year;¹³ and
4
5 Whereas, Only 14.5% of assault survivors were offered PEP, and only 8.5% of uninsured
6 assault survivors were offered PEP in a 2009 survey of 117 Los Angeles Emergency
7 Departments;¹⁴ and
8
9 Whereas, A 2018 meta-analysis found that the nationally pooled mean of individuals who were
10 sexually assaulted and offered PEP at studied emergency departments was 55.9%;¹⁵ and
11
12 Whereas, There is no national consensus on emergency medicine residents' education about
13 sexual assault examinations, which results in suboptimal care for the survivors of sexual
14 assaults;^{13,16,17,18,19} and
15
16 Whereas, A qualitative study in 2016 of sexual assault patients found that physicians neglecting
17 to offer PEP is a major barrier to patient access, disproportionately affecting those who are
18 homeless or uninsured;^{11,20} and
19
20 Whereas, The same study indicated that the physicians neglected to offer PEP or they provided
21 incorrect counseling due to a lack of knowledge about state or national PEP guidelines and a
22 2013 study found 20% of emergency physicians were not aware CDC PEP guidelines;^{20,21} and
23
24 Whereas, The cost of PEP is between \$600-\$1000, and persons prescribed PEP after sexual
25 assault can be reimbursed for medications and clinical care costs through state Crime Victim's
26 Compensation Programs funded by the U.S. Department of Justice;^{22,23,24} and

¹³ Ashlesha Patel et al., "Assessing the Extent of Provision of Comprehensive Medical Care Management for Female Sexual Assault Patients in US Hospital Emergency Departments," *International Journal of Gynecology & Obstetrics* 123, no. 1 (October 2013): 24–28, doi:10.1016/j.ijgo.2013.04.014.

¹⁴ Raphael J. Landovitz, Kory B. Combs, and Judith S. Currier, "Availability of HIV Postexposure Prophylaxis Services in Los Angeles County," *Clinical Infectious Diseases* 48, no. 11 (June 1, 2009): 1624–27, doi:10.1086/598976.

¹⁵ Meredith Scannell, Tiffany Kim, and Barbara J. Guthrie, "A Meta-Analysis of HIV Postexposure Prophylaxis Among Sexually Assaulted Patients in the United States," *Journal of the Association of Nurses in AIDS Care* 29, no. 1 (January 2018): 60–69, doi:10.1016/j.jana.2017.10.004.

¹⁶ Margaret K Sande et al., "Sexual Assault Training in Emergency Medicine Residencies: A Survey of Program Directors.," *The Western Journal of Emergency Medicine* 14, no. 5 (September 2013): 461–66, doi:10.5811/westjem.2013.2.12201.

¹⁷ Samantha Schilling et al., "Testing and Treatment After Adolescent Sexual Assault in Pediatric Emergency Departments.," *Pediatrics* 136, no. 6 (December 2015): e1495–503, doi:10.1542/peds.2015-2093.

¹⁸ Monika K Goyal et al., "Enhancing the Emergency Department Approach to Pediatric Sexual Assault Care: Implementation of a Pediatric Sexual Assault Response Team Program.," *Pediatric Emergency Care* 29, no. 9 (September 2013): 969–73, doi:10.1097/PEC.0b013e3182a21a0d.

¹⁹ R. C. Merchant et al., "Compliance in Rhode Island Emergency Departments With American Academy of Pediatrics Recommendations for Adolescent Sexual Assaults," *PEDIATRICS* 121, no. 6 (June 1, 2008): e1660–67, doi:10.1542/peds.2007-3100.

²⁰ Valentina Djelaj, Debra Patterson, and Christina M. Romero, "A Qualitative Exploration of Sexual Assault Patients' Barriers to Accessing and Completing HIV Prophylaxis," *Journal of Forensic Nursing* 13, no. 2 (2017): 45–51, doi:10.1097/JFN.0000000000000153.

²¹ Allan E Rodriguez et al., "HIV Medical Providers' Perceptions of the Use of Antiretroviral Therapy as Nonoccupational Postexposure Prophylaxis in 2 Major Metropolitan Areas.," *Journal of Acquired Immune Deficiency Syndromes* (1999) 64 Suppl 1, no. 0 1 (November 1, 2013): S68-79, doi:10.1097/QAI.0b013e3182a901a2.

²² Office for Victims of Crime, "U.S. Resource Map of Crime Victim Services & Information," *Office of Justice Programs*, 2016, <https://ojp.gov/ovc/map.html>.

²³ Michigan Department of Health & Human Services, "Crime Victim Services," *Crime Victim Services*, 2018, http://www.michigan.gov/mdhhs/0,5885,7-339-71548_54783_54853---,00.html.

²⁴ Office of Epidemiology & Prevention Services, "Post-Exposure Prophylaxis (PEP) FAQs," *West Virginia Department of Health & Human Resources*, 2018, [https://dhhr.wv.gov/oeps/std-hiv-hep/needlestick/Pages/Post-ExposureProphylaxis\(PEP\)FAQs.aspx](https://dhhr.wv.gov/oeps/std-hiv-hep/needlestick/Pages/Post-ExposureProphylaxis(PEP)FAQs.aspx).

1 Whereas, The estimated lifetime cost for HIV treatment was \$367,134 in 2009 and \$379,668 in
2 2010, and the estimated medical cost saved by preventing one HIV infection is \$229,800;^{25,26}
3 and

4
5 Whereas, Many living with HIV may find it challenging to perform daily tasks, participate in
6 moderate physical activities, or have the energy to engage in an active social life;²⁷ therefore be
7 it

8
9 RESOLVED, That our American Medical Association advocate for education of physicians
10 about the effective use of HIV Post-Exposure Prophylaxis (PEP) and the U.S. PEP Clinical
11 Practice Guidelines (New HOD Policy); and be it further

12
13 RESOLVED, That our AMA support increased public education about the effective use of Post-
14 Exposure Prophylaxis for HIV (New HOD Policy); and be it further

15
16 RESOLVED, That our AMA amend policy H-20.900 by addition and deletion as follows:

17
18 **H-20.900, “HIV, Sexual Assault, and Violence”**

19 Our AMA believes that HIV testing and Post-Exposure Prophylaxis (PEP) should be
20 offered to all victims survivors of sexual assault, that these victims survivors should be
21 encouraged to be retested in six months if the initial test is negative, and that strict
22 confidentiality of test results be maintained. (Modify Current HOD Policy)

Fiscal note: Minimal - less than \$1,000.

Date Received: 09/21/18

RELEVANT AMA POLICY:

E-8.1 Routine Universal Screening for HIV

Physicians primary ethical obligation is to their individual patients. However, physicians also have a long-recognized responsibility to participate in activities to protect and promote the health of the public. Routine universal screening of adult patients for HIV helps promote the welfare of individual patients, avoid injury to third parties, and protect public health.

Medical and social advances have enhanced the benefits of knowing ones HIV status and at the same time have minimized the need for specific written informed consent prior to HIV testing. Nonetheless, the ethical tenets of respect for autonomy and informed consent require that physicians continue to seek patients informed consent, including informed refusal of HIV testing.

To protect the welfare and interests of individual patients and fulfill their public health obligations in the context of HIV, physicians should:

- (a) Support routine, universal screening of adult patients for HIV with opt-out provisions.
- (b) Make efforts to persuade reluctant patients to be screened, including explaining potential benefits to the patient and to the patients close contacts.
- (c) Continue to uphold respect for autonomy by respecting a patients informed decision to opt out.
- (d) Test patients without prior consent only in limited cases in which the harms to individual autonomy are offset by significant benefits to known third parties, such as testing to protect occupationally exposed health care professionals or patients.
- (e) Work to ensure that patients who are identified as HIV positive receive appropriate follow-up care and counseling.
- (f) Attempt to persuade patients who are identified as HIV positive to cease endangering others.

²⁵ CDC Division of HIV/AIDS Prevention, “HIV Cost-Effectiveness,” *HIV/AIDS*, 2017, <https://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html>.

²⁶ Bruce R Schackman et al., “The Lifetime Medical Cost Savings from Preventing HIV in the United States.,” *Medical Care* 53, no. 4 (April 2015): 293–301, doi:10.1097/MLR.0000000000000308.

²⁷ K H Basavaraj, M A Navya, and R Rashmi, “Quality of Life in HIV/AIDS.,” *Indian Journal of Sexually Transmitted Diseases* 31, no. 2 (July 2010): 75–80, doi:10.4103/0253-7184.74971.

(g) Be aware of and adhere to state and local guidelines regarding public health reporting and disclosure of HIV status when a patient who is identified as HIV positive poses significant risk of infecting an identifiable third party. The doctor may, if permitted, notify the endangered third party without revealing the identity of the source person.

(h) Safeguard the confidentiality of patient information to the greatest extent possible when required to report HIV status.

[AMA Principles of Medical Ethics: I, VI, VII](#)

Issued: 2016

Sexual Assault Survivor Services H-80.998

Our AMA supports the function and efficacy of sexual assault survivor services, supports state adoption of the sexual assault survivor rights established in the Survivors' Bill of Rights Act of 2016, encourages sexual assault crisis centers to continue working with local police to help sexual assault survivors, and encourages physicians to support the option of having a counselor present while the sexual assault survivor is receiving medical care.

Citation: Res. 56, A-83; Reaffirmed: CLRDPD Rep. 1, I-93; Reaffirmed: CSA Rep. 8, A-05; Reaffirmed: CSAPH Rep. 1, A-15; Modified: Res. 202, I-17

HIV, Sexual Assault, and Violence H-20.900

Our AMA believes that HIV testing should be offered to all victims of sexual assault, that these victims should be encouraged to be retested in six months if the initial test is negative, and that strict confidentiality of test results be maintained.

Citation: (CSA Rep. 4, A-03; Modified: CSAPH Rep. 1, A-13)

Access to Emergency Contraception H-75.985

It is the policy of our AMA: (1) that physicians and other health care professionals should be encouraged to play a more active role in providing education about emergency contraception, including access and informed consent issues, by discussing it as part of routine family planning and contraceptive counseling; (2) to enhance efforts to expand access to emergency contraception, including making emergency contraception pills more readily available through pharmacies, hospitals, clinics, emergency rooms, acute care centers, and physicians' offices; (3) to recognize that information about emergency contraception is part of the comprehensive information to be provided as part of the emergency treatment of sexual assault victims; (4) to support educational programs for physicians and patients regarding treatment options for the emergency treatment of sexual assault victims, including information about emergency contraception; and (5) to encourage writing advance prescriptions for these pills as requested by their patients until the pills are available over-the-counter.

Citation: (CMS Rep. 1, I-00; Appended: Res. 408, A-02; Modified: Res. 443, A-04; Reaffirmed: CSAPH Rep. 1, A-14)

HIV Postexposure Prophylaxis for Medical Students During Electives Abroad D-295.970

Our AMA: (1) recommends that US medical schools ensure that medical students who engage in clinical rotations abroad have immediate access to HIV prophylaxis; and (2) encourages medical schools to provide information to medical students regarding the potential health risks of completing a medical rotation abroad, and on the appropriate precautions to take to minimize such risks.

Citation: (Res. 303, A-02; Reaffirmed: CCB/CLRDPD Rep. 4, A-12)

Pre-Exposure Prophylaxis (PrEP) for HIV H-20.895

1. Our AMA will educate physicians and the public about the effective use of pre-exposure prophylaxis for HIV and the US PrEP Clinical Practice Guidelines.
2. Our AMA supports the coverage of PrEP in all clinically appropriate circumstances.
3. Our AMA supports the removal of insurance barriers for PrEP such as prior authorization, mandatory consultation with an infectious disease specialist and other barriers that are not clinically relevant.
4. Our AMA advocates that individuals not be denied any insurance on the basis of PrEP use.

Citation: Res. 106, A-16; Modified: Res. 916, I-16; Appended: Res. 101, A-17

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 906
(I-18)

Introduced by: Medical Student Section

Subject: Increased Access to Identification Cards for the Homeless Population

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, More than 3.5 million Americans will experience homelessness at some point in a
2 given year, and 77,486 of these individuals are chronically homeless;^{1,2} and

3
4 Whereas, The AMA supports public policy initiatives pertaining to access to care, and in
5 particular supports improving health outcomes and decreasing health care costs for the
6 homeless population (H-160.903, H-160.798, H-345.975, H-185.944); and

7
8 Whereas, Lack of identification serves as a major barrier for homeless individuals seeking
9 medical care, in particular preventing them from enrolling in Medicaid, with 45.1% of the
10 homeless without photo identification denied access to Medicaid or medical services;^{3,4,5} and

11
12 Whereas, Over 36% of the U.S. homeless population suffers from a severe mental illness or
13 chronic substance abuse, and lack of identification among the homeless prevents them from
14 accessing drug treatment and rehabilitation programs;^{6,7} and

15
16 Whereas, Forty-three states allow for pharmacists to require photograph identification from
17 individuals prior to dispensing prescription drugs;⁸ and

18
19 Whereas, Unsheltered homeless individuals often have poorer health, less access to
20 healthcare, and an increased risk of premature mortality compared to the sheltered homeless;⁹
21 and

¹ National Law Center on Homelessness & Poverty. (2004). *Photo Identification Barriers Faced by Homeless Persons: The Impact of September 11*. Washington, DC. <https://www.nlchp.org/documents/ID_Barriers>

² Department of Housing and Urban Development. (2017). *Sheltered Homeless Persons in Detroit (MI) 10/1/2016 - 9/30/2017*. Detroit: 2017 Annual Homeless Assessment Report.

<<https://static1.squarespace.com/static/5344557fe4b0323896c3c519/t/5a7c751608522985c2a3c780/1518105882011/2017+AHAR+All+Persons+Report+FINAL+from+HDX.pdf>>

³ Michigan Commission on Community Action and Economic Opportunity. (2016). *State Identification Cards*. Michigan Department of Health and Human Services.

<https://www.michigan.gov/documents/mdhhs/Commission_Report_State_Identification_Cards_552059_7.pdf>

⁴ National Law Center on Homelessness & Poverty. (2004). *Photo Identification Barriers Faced by Homeless Persons: The Impact of September 11*. Washington, DC. <https://www.nlchp.org/documents/ID_Barriers>

⁵ Kaiser Commission on Medicaid and the Uninsured. (2012). *Medicaid Coverage and Care for the Homeless Population: Key Lessons to Consider for the 2014 Medicaid Expansion*. Washington, DC: The Henry J. Kaiser Family Foundation.

<<https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8355.pdf>>

⁶ Kaiser Commission on Medicaid and the Uninsured. (2012). *Medicaid Coverage and Care for the Homeless Population: Key Lessons to Consider for the 2014 Medicaid Expansion*. Washington, DC: The Henry J. Kaiser Family Foundation.

<<https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8355.pdf>>

⁷ Peterson JA, S. R. (2010). Why don't out-of-treatment individuals enter methadone treatment programs? The International journal on drug policy. *International Journal of Drug Policy*, (21)1:36-42.

⁸ National Alliance for Model State Drug Laws. (2018). *States that Require ID Prior to Dispensing Controlled Substances or Non-Controlled Prescription Drugs*. Charlottesville: Office of National Drug Control Policy. <<http://www.namsdl.org/library/052D1242-E158-6B44-A6E69A0729BCDF0C>>

⁹ Montgomery, A. E., Szymkowiak, D., Marcus, J., Howard, P., & Culhane, D. P. (2016). Homelessness, Unsheltered Status, and Risk Factors for Mortality: Findings From the 100 000 Homes Campaign. *Public Health Reports*, 131(6), 765-772.
doi:10.1177/0033354916667501

1 Whereas, The National Law Center on Homelessness and Poverty found that 54.1% of
2 homeless individuals were denied housing or shelter due to lack of identification;¹⁰ and
3
4 Whereas, Recent national surveys have shown that 28% of homeless individuals do not get
5 enough to eat, with 40% report going one or more days without food due to the inability to afford
6 it;¹¹ and
7
8 Whereas, Lack of identification can prevent homeless individuals who qualify for Supplemental
9 Nutrition Assistance Program (SNAP) benefits from accessing this service, as the application
10 process requires personal identification; as a result, only 37% of the homeless population
11 receives SNAP benefits;¹² and
12
13 Whereas, Lack of identification causes homeless individuals to delay care due to lack of
14 insurance, and therefore has a systemic economic impact through increased emergency
15 department utilization and presentation in more advanced disease stages;^{13,14} and
16
17 Whereas, The Medicaid application process includes verifying the applicant's Social Security
18 Number, yet a replacement Social Security card requires a form of identification such as driver's
19 license, state-issued non-driver identification card, or U.S. passport;^{15,16} and
20
21 Whereas, The average application fees to obtain a birth certificate and passport in the U.S. are
22 \$15.81 and \$97, respectively;¹⁷ and
23
24 Whereas, A national study found that 36% of homeless individuals could not obtain a photo
25 identification because they could not afford it;¹⁸ and
26
27 Whereas, The state of California passed a law allowing homeless individuals to obtain free
28 photo identification, and a number of other state legislatures are in the process of doing the
29 same;^{19,20,21,22,23} therefore be it

¹⁰ National Law Center on Homelessness & Poverty. (2004). *Photo Identification Barriers Faced by Homeless Persons: The Impact of September 11*. Washington, DC. <https://www.nlchp.org/documents/ID_Barriers>

¹¹ Rosen, J., Hoey, R., & Steed, T. (2000). Food stamp and SSI benefits: Removing access barriers for homeless people. *Clearinghouse Rev.*, 34, 679.

¹² Rosen, J., Hoey, R., & Steed, T. (2000). Food stamp and SSI benefits: Removing access barriers for homeless people. *Clearinghouse Rev.*, 34, 679.

¹³ Kaiser Commission on Key Facts. (2012). *The Uninsured And The Difference Health Insurance Makes*. Washington, DC: Henry J Kaiser Family Foundation. <<https://www.kff.org/health-reform/fact-sheet/the-uninsured-and-the-difference-health-insurance/>>

¹⁴ Hwang, S., & Henderson, M. J. (2010). Health care utilization in homeless people: translating research into policy and practice. *Agency for Healthcare Research and Quality Working Paper*, (10002). <https://meps.ahrq.gov/data_files/publications/workingpapers/wp_10002.pdf>

¹⁵ Wilkins, C., Burt, M. R., & Locke, G. (2014). *A Primer on Using Medicaid for People Experiencing Chronic Homelessness and Tenants in Permanent Supportive Housing*. Office of the Assistant Secretary for Planning and Evaluation.

¹⁶ Social Security Administration. (2018). *Social Security Administration*. Retrieved from Learn what documents you will need to get a Social Security Card: <https://www.ssa.gov/ssnumber/ss5doc.htm>

¹⁷ Department of Homeland Security Regulatory Evaluation. (2008). *Regulatory Evaluation for REAL ID Program*. Department of Homeland Security. <<https://www.regulations.gov/document?D=DHS-2006-0030-10704>>

¹⁸ National Law Center on Homelessness & Poverty. (2004). *Photo Identification Barriers Faced by Homeless Persons: The Impact of September 11*. Washington, DC. <https://www.nlchp.org/documents/ID_Barriers>

¹⁹ State of California Department of Motor Vehicles. (2018). *Is There a Fee? FFDL 6 Requirements for a California Identification Card*. California. <https://www.dmv.ca.gov/portal/dmv/detail/pubs/brochures/fast_facts/ffd106>

²⁰ Hawaii Senate Bill 11. S 346. 29th Legislature. (2017). <<https://legiscan.com/HI/bill/SB11/2017>>

²¹ An Act to provide identification to homeless youth and families. S.1906. 190th General Court of the Commonwealth of Massachusetts. (2017). <<https://malegislature.gov/Bills/190/H2737.Html>>

²² Texas House Bill 3354. Relating to the fee for a driver's license or personal identification certificate for a homeless individual. Texas House of Representatives. 85th Legislature. (2017). <<https://legiscan.com/TX/text/HB3354/id/1559665>>

²³ West Virginia H.B. 2215. West Virginia House of Representatives. (2017). <http://www.wvlegislature.gov/Bill_Status/bills_text.cfm?billdoc=hb2215%20intr.htm&yr=2017&sesstype=RS&i=2215>

1 RESOLVED, That our American Medical Association recognize that among the homeless
2 population, lack of identification serves as a barrier to accessing medical care and fundamental
3 services that support health (New HOD Policy); and be it further

4
5 RESOLVED, That our AMA support legislative and policy changes that streamline, simplify, and
6 reduce or eliminate the cost of obtaining identification cards for the homeless population. (New
7 HOD Policy)

Fiscal Note: Minimal - less than \$1,000.

Date Received: 09/21/18

RELEVANT AMA POLICY

The Mentally Ill Homeless H-160.978

(1) The AMA believes that public policy initiatives directed to the homeless, including the homeless mentally ill population, should include the following components: (a) access to care (e.g., integrated, comprehensive services that permit flexible, individualized treatment; more humane commitment laws that ensure active inpatient treatment; and revisions in government funding laws to ensure eligibility for homeless persons); (b) clinical concerns (e.g., promoting diagnostic and treatment programs that address common health problems of the homeless population and promoting care that is sensitive to the overriding needs of this population for food, clothing, and residential facilities); (c) program development (e.g., advocating emergency shelters for the homeless; supporting a full range of supervised residential placements; developing specific programs for multiproblem patients, women, children, and adolescents; supporting the development of a clearinghouse; and promoting coalition development); (d) educational needs; (e) housing needs; and (f) research needs. (2) The AMA encourages medical schools and residency training programs to develop model curricula and to incorporate in teaching programs content on health problems of the homeless population, including experiential community-based learning experiences. (3) The AMA urges specialty societies to design interdisciplinary continuing medical education training programs that include the special treatment needs of the homeless population.

Citation: BOT Rep. LL, A-86; Reaffirmed: Sunset Report, I-96; Reaffirmed: CMS Rep. 8, A-06; Reaffirmed: CMS Rep. 01, A-16

Eradicating Homelessness H-160.903

Our American Medical Association: (1) supports improving the health outcomes and decreasing the health care costs of treating the chronically homeless through clinically proven, high quality, and cost effective approaches which recognize the positive impact of stable and affordable housing coupled with social services; (2) recognizes that stable, affordable housing as a first priority, without mandated therapy or services compliance, is effective in improving housing stability and quality of life among individuals who are chronically-homeless; (3) recognizes adaptive strategies based on regional variations, community characteristics and state and local resources are necessary to address this societal problem on a long-term basis; (4) recognizes the need for an effective, evidence-based national plan to eradicate homelessness; and (5) encourages the National Health Care for the Homeless Council to study the funding, implementation, and standardized evaluation of Medical Respite Care for homeless persons.

Citation: Res. 401, A-15; Appended: Res. 416, A-18; Modified: BOT Rep. 11, A-18

Maintaining Mental Health Services by States H-345.975

Our AMA:

1. supports maintaining essential mental health services at the state level, to include maintaining state inpatient and outpatient mental hospitals, community mental health centers, addiction treatment centers, and other state-supported psychiatric services;
2. supports state responsibility to develop programs that rapidly identify and refer individuals with significant mental illness for treatment, to avoid repeated psychiatric hospitalizations and repeated interactions with the law, primarily as a result of untreated mental conditions;
3. supports increased funding for state Mobile Crisis Teams to locate and treat homeless individuals with mental illness;
4. supports enforcement of the Mental Health Parity Act at the federal and state level; and
5. will take these resolves into consideration when developing policy on essential benefit services.

Citation: (Res. 116, A-12; Reaffirmation A-15)

Subscriber Identification Cards H-185.944

Our AMA: (1) urges any pertinent official or governmental agency to require health insurance plans to issue identification cards to its subscribers which prominently identify the full legal name of the insured; name of the policy holder; identification numbers needed for claim submission; and the primary insurance company name with its appropriate mailing address; and (2) will advocate for legislative and regulatory sanctions against insurance companies which present obstacles to the timely filing of claims which result in the denial of benefits.

Citation: (Sub. Res. 716, A-10; Modified: Sub. Res. 715, A-15)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 908
(I-18)

Introduced by: Medical Student Section

Subject: Increasing Accessibility to Incontinence Products

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, As sales of adult incontinence products and baby diapers are projected to increase
2 48% and 2.6% respectively by 2020, more individuals and families in both populations face
3 similar challenges to accessing necessary incontinence products;¹ and
4
5 Whereas, Lack of access to necessary incontinence products leads to prolonged use of
6 soiled diapers, which precipitates health problems including recurrent urinary tract infections,
7 diaper dermatitis, or exacerbation of eczema, leading to an increase in physician's office and
8 emergency room visits;^{2,3} and
9
10 Whereas, Diaper need, defined as lacking the financial means to purchase an adequate
11 supply of diapers, is a widespread issue affecting parents of all ethnicities and economic
12 statuses, especially those living below the poverty line;⁴ and
13
14 Whereas, Among children using diapers, 23% are members of families earning less than
15 100% of the federal poverty level and an additional 23% live in families earning 100% to
16 200% of the federal poverty level;^{1,5} and
17
18 Whereas, The national average cost of diapers is \$936 annually, the equivalent of 14% of
19 national average annual income;^{2,6} and
20
21 Whereas, Diaper need occurs more frequently in parents with mental health needs and
22 contributes to parental stress and depression, factors which in turn have been known to
23 increase the risk of a child's future behavioral, social, and emotional problems;^{3,4} and
24
25 Whereas, Adult incontinence product use is increasing, with the Urology Care Foundation
26 estimating that 25% to 33% of all people in the U.S. suffer from some degree of urinary
27 incontinence, with more than 50% of individuals over 65 having experienced incontinence;^{7,8}
28 and

¹ Hymowitz C, Lochner-Coleman L. The Adult Diaper Market is About to Take Off. *Bloomberg*. February 11, 2016.

² Porter S, Steelfel L. Diaper need: A change for better health. *Pediatric Nursing*. 2015;41(3):141.

³ Fujimura T, Makino M, Takagi M, et al. The influence of incontinence on the characteristic properties of the skin in bedridden elderly subjects. *International Journal of Dermatology*. 2016;55(5):e234-240.

⁴ Raver C, Letourneau N, Scott J, D'Agostino H. Huggies every little bottom study: Diaper need in the US and Canada. Commissioned by Huggies®, a Kimberly-Clark company. 2010.

⁵ Diaper Need in America. National Diaper Bank Network. Accessed at <https://nationaldiaperbanknetwork.org/what-is-diaper-need/>.

⁶ Smith MV, Kruse A, Weir A, Goldblum J. Diaper need and its impact on child health. *Pediatrics*. 2013;132(2):253.

⁷ Urology Care Foundation: What is urinary incontinence? <https://www.urologyhealth.org/urologic-conditions/urinary-incontinence>. Accessed March 26, 2018.

⁸ Alameda County Board of Supervisors. Legislative Position Request Form. January 11, 2016.

1 Whereas, Of the 43 million Americans over 65 years of age, 9.4% are living below the federal
2 poverty level;¹ and
3
4 Whereas, Seniors can expect to spend approximately \$1800 annually on adult diapers, and
5 for low-income individuals this expense "can consume over 10 percent of their annual
6 income";⁹ and
7
8 Whereas, Studies have found that incontinence is detrimental to quality of life through its
9 impact on relationships, self-esteem, employment, travel, and social activities;^{10,11,12} and
10
11 Whereas, 18 states have already eliminated sales tax on adult incontinence products and 13
12 states have eliminated sales tax on diapers by classifying them as medical supplies or
13 clothing, exempting them as medical prescriptions, or having no sales tax at all;²¹ and
14
15 Whereas, 32 states still charge sales tax on adult incontinence products and 37 states still
16 charge sales tax on diapers, with the sales tax as high as 7.25 percent;¹³ and
17
18 Whereas, Multiple pieces of state and federal legislation have proposed to increase access to
19 adult incontinence products and diapers by removing state taxes, aiding low-income families
20 in purchasing necessary products, and increasing insurance coverage through Medicare and
21 Medicaid; however none have currently passed;^{14,15,16,17,18} and
22
23 Whereas, Our AMA already supports the removal of all sales tax on feminine hygiene
24 products in order to increase access to necessary medical products, especially for those who
25 live below the federal poverty line (H-270.953); therefore be it
26
27 RESOLVED, That our American Medical Association support increased access to affordable
28 incontinence products. (New HOD Policy)

Fiscal note: Minimal - less than \$1,000.

Received: 09/24/18

⁹ Alameda County Board of Supervisors. Legislative Position Request Form. January 11, 2016.

¹⁰ Fisher, K. et al. Comparison of Recall and Daily Self-Report of Fecal Incontinence Severity. *J Wound Ostomy Continence Nurs.* 2008 Sept-Oct;35(5):515-20.

¹¹ Alimohammadian, M. et al. Suffering in silence: a community-based study of fecal incontinence in women. *Int J Colorectal Dis.* 2014 Mar;29(3):401-6.

¹² Halland, M. et al. Prevalence correlates and impact of fecal incontinence among older women. *Dis Colon Rectum.* 2013 Sep;56(9): 1080-6.

¹³ Weir, AM. Fifty state survey on the sales tax treatment of diapers. *National Diaper Bank Network.* January 9, 2017.

¹⁴ Hellmann J. Illinois lawmaker wants to cut tax on diapers, baby wipes. *Chicago Tribune.* February 6, 2015.

¹⁵ Coffey D. Legislators seek to make diapers exempt from state sales tax. *Hartford Courant.* February 2, 2015.

¹⁶ Vitale, Joseph F. State Concurrent Resolution No. 53. State of New Jersey. Introduced January 16, 2018.

¹⁷ Hygiene Assistance for Families of Infants and Toddlers Act of 2016, H.R. H.R.4055, 114th Cong. June 16, 2016.

¹⁸ Hygiene Assistance for Families of Infants and Toddlers Act of 2015, H.R. H.R.4055, 114th Cong. November 18, 2015.

RELEVANT AMA POLICY:

Tax Exemptions for Feminine Hygiene Products H-270.953

Our AMA supports legislation to remove all sales tax on feminine hygiene products.

Citation: Res. 215, A-16

Insurance Coverage for Complete Maternity Care H-185.997

Our AMA (1) reaffirms its policy of encouraging health insurance coverage for care of the newborn from the moment of birth;

(2) urges the health insurance industry and government to include in their plans, which provide maternity benefits, coverage for normal obstetrical care, and all obstetrical complications including necessary intrauterine evaluation and care of the unborn infant;

(3) urges the health insurance industry to offer such plans on the broadest possible basis;

(4) urges the health insurance industry to make available, on an optional basis, coverage for treatment associated with voluntary control of reproduction;

(5) will advocate for expanding coverage of maternity care to dependent women under the age of 26 on their parents' large group plans; and

(6) will advocate that individual, small and large group health plans provide 60 days of newborn coverage for all newborns born to participants in the plan.

Citation: (BOT Rep. M, CMS Rep. J, I-74; Reaffirmed: CLRPD Rep. C, A-89; Reaffirmed: Sunset Report, A-00; Reaffirmed: Res. 103, A-09; Appended: Res. 101, A-14)

Opposition to Proposed Budget Cuts in WIC and Head Start H-245.979

The AMA opposes reductions in funding for WIC and Head Start and other programs that significantly impact child and infant health and education.

Citation: (Res. 246, I-94; Reaffirmed: BOT Rep. 29, A-04; Reaffirmed: BOT Rep. 19, A-14)

Expanding Enrollment for the State Children's Health Insurance Program (SCHIP) H-290.971

Our AMA continues to support:

a. health insurance coverage of all children as a strategic priority;

b. efforts to expand coverage to uninsured children who are eligible for the State Children's Health Insurance Program (SCHIP) and Medicaid through improved and streamlined enrollment mechanisms;

c. the reauthorization of SCHIP in 2007; and

d. supports the use of enrollment information for participation in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and/or the federal school lunch assistance program as documentation for SCHIP eligibility in order to allow families to avoid duplication and the cumbersome process of re-documenting income for child health coverage.

Citation: (Res. 118, A-07; CMS Rep. 1, A-07; Reaffirmation A-14)

Adequate Funding of the WIC Program H-245.989

Our AMA urges the U.S. Congress to investigate recent increases in the cost of infant formula, as well as insure that WIC programs receive adequate funds to provide infant formula and foods for eligible children.

Citation: (Res. 269, A-90; Reaffirmed: Sunset Report, I-00; Reaffirmed: CSAPH Rep. 1, A-10)

Dignity and Self Respect H-25.997

The AMA believes that medical care should be available to all our citizens, regardless of age or ability to pay, and believes ardently in helping those who need help to finance their medical care costs.

Furthermore, the AMA believes in preserving dignity and self respect of all individuals at all ages and believes that people should not be set apart or isolated on the basis of age. The AMA believes that the experience, perspective, wisdom and skill of individuals of all ages should be utilized to the fullest.

Citation: AMA President's Address, A-61; Reaffirmed: CLRPD C, A-88; Reaffirmed: Sunset Report, I-98; Reaffirmed: CMS Rep. 4, A-08; Modified: CEJA Rep. 06, A-18

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 911
(I-18)

Introduced by: Resident and Fellow Section

Subject: Regulating Tattoo and Permanent Makeup Inks

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, Almost a fourth of men and women between the age of 18 and 50 currently have a
2 tattoo¹; and

4 Whereas, The Food and Drug Administration regulates cosmetics, which are generally pigments
5 used on the surface of the skin, but does not regulate tattoo and permanent makeup inks which
6 are pigments injected with needles below the skin's surface²; and

7 Whereas, Some risks, such as the spread of infections through the use of unsterilized needles,
8 have long been known²; and

10 Whereas, The long term safety of permanent tattoo inks has not been previously studied²; and

12 Whereas, Research has also shown that some pigment migrates from the tattoo site to the
14 body's lymph nodes²; and

16 Whereas, Many pigments used in tattoo inks are industrial-grade colors suitable for printers' ink
17 or automobile paint²; and

19 Whereas, Azo pigments, the organic pigments making up about 60% of the colorants in tattoo
20 inks are not of health concern while chemically intact, they can degrade with the help of bacteria
21 or ultraviolet light and potentially can turn into cancer-causing primary aromatic amines; and

23 Whereas, Some surveys show that up to 50% of tattoo owners come to regret getting a tattoo;
24 and

26 Whereas, Lasers are often used to blast apart pigments, sending problematic degradation
27 products into the body and researchers do not know how the degradation products are
28 distributed in the body or how they get excreted; and

30 Whereas, A study by the Australian government's National Industrial Chemical's Notification and
31 Assessment Scheme (NICNAS) showed the presence of polycyclic aromatic hydrocarbons
32 (PAHs), a group of chemicals known to be carcinogens in more than one-fifth of 49 inks tested
33 and in 83% of the black inks tested³; and

35 Whereas, Tattoo inks may also contain potentially harmful metal impurities such as chromium,
36 nickel, copper, and cobalt; and

38 Whereas, Manufacturers of tattoo and permanent makeup inks in the United States are often
39 protected from divulging the ingredients of tattoo inks under the guise of considering them
40 'trademark secrets'; and

1 Whereas, In 2008, the Council of Europe, an organization focused on promoting human rights
2 and the integration of regulatory functions in the continent, recommended policies to ensure the
3 safety of tattoos and permanent makeup, which advocate the banning of sixty-two hazardous
4 chemicals, as well as guidelines which include that tattoo and permanent makeup products
5 should contain the following information on the packaging: the name and address of the
6 manufacturer or the person responsible for placing the product on the market, the date of
7 minimum durability⁴, the conditions of use and warnings, the batch number or other reference
8 used by the manufacturer for batch identification, the list of ingredients according to their
9 International Union of Pure and Applied Chemistry (IUPAC) name, CAS Number (chemical
10 Abstract Service of the American Chemical Society) or Colour index (CI) number, and the
11 guarantee of sterility of the contents⁵; and
12
13 Whereas, AMA policy H-440.909, "Regulation of Tattoo Artists and Facilities," currently only
14 encourages the state regulation of tattoo artists and tattoo facilities to ensure adequate
15 procedures to protect the public health, and encourages physicians to report all adverse
16 reactions associated with tattooing to the Food and Drug Administration MedWatch program; and
17
18 Whereas, Current regulation of tattoo and permanent makeup inks in the United States
19 performed at state or provincial levels generate a wide variety of guidelines and hygiene
20 standards; therefore be it
21
22 RESOLVED, That our American Medical Association encourage the Food and Drug
23 Administration to adopt regulatory standards for tattoo and permanent makeup inks that include
24 at minimum the disclosures expected for injectable drugs and cosmetics and mandate that this
25 information be available to both the body licensed to perform the tattoo and to the person
26 receiving the tattoo (New HOD Policy); and be it further
27
28 RESOLVED, That our AMA study the safety of any chemical in tattoo and permanent makeup
29 inks. (Directive to Take Action)

Fiscal Note: Modest - between \$1,000 - \$5,000.

Received: 09/27/18

References:

- ¹ [Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. Journal of the American Academy of Dermatology. 2006 Sep 30;55\(3\):413-21.](#)
- ² <https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048919.htm>
- ³ <http://theconversation.com/one-in-five-tattoo-inks-in-australia-contain-carcinogenic-chemicals-63947>
- ⁴ [Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. Journal of the American Academy of Dermatology. 2006 Sep 30;55\(3\):413-21.](#)
- ⁵ https://search.coe.int/cm/Pages/result_details.aspx?ObjectID=09000016805d3dc4

RELEVANT AMA POLICY

H-440.909 Regulation of Tattoo Artists and Facilities

The AMA encourages the state regulation of tattoo artists and tattoo facilities to ensure adequate procedures to protect the public health; and encourages physicians to report all adverse reactions associated with tattooing to the Food and Drug Administration MedWatch program. (Res. 506, A-96; Reaffirmed: CSAPH Rep. 3, A-06; Reaffirmed: CSAPH Rep. 01, A-16)

H-440.934 Adequacy of Sterilization in Commercial Enterprises

The AMA requests that state health departments ensure the adequacy of sterilization of instruments used in commercial enterprises (tattoo parlors, beauty salons, barbers, manicurists, etc.) because of the danger of exchange of infected blood-contaminated fluids. (Sub. Res. 409, I-92; Reaffirmed: CSA Rep. 8, A-03; Modified: CSAPH Rep. 1, A-13)

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 912
(I-18)

Introduced by: Resident and Fellow Section
Subject: Comprehensive Breast Cancer Treatment
Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, The Women's Health and Cancer Rights Act of 1998 (WHCRA) mandates that
2 insurance providers cover reconstructive procedures after mastectomy; and
3
4 Whereas, Some insurers have interpreted this language as only covering total mastectomies
5 and not partial mastectomies or lumpectomies and thus deny coverage of reconstructive
6 surgery for patients with deformities after lumpectomies and after radiation; and
7
8 Whereas, Breast conservation therapy is often an oncologically safe option for patients, which
9 may leave the breast disfigured; and
10
11 Whereas, Radiation therapy in and of itself can lead to pain, fibrosis and deformity of a post-
12 treatment breast; and
13
14 Whereas, Technology and techniques for correcting post-lumpectomy and post-radiation
15 deformities have improved and increased, yet insurance interpretation of the WHCRA benefit
16 may limit women's access to corrective surgery, oncoplastic reconstruction and fat grafting; and
17
18 Whereas, Breast reconstruction has been shown to significantly increase physical, social and
19 sexual well-being¹; therefore be it
20
21 RESOLVED, That our AMA amend Policy H-55.973, "Breast Reconstruction," by addition and
22 deletion as follows:
23
24 Our AMA: (1) believes that reconstruction of the breast for rehabilitation of the
25 ~~postmastectomy cancer post-treatment patient with in situ or invasive breast neoplasm~~
26 should be considered reconstructive surgery rather than aesthetic surgery; (2)
27 supports education for physicians and breast cancer patients on breast reconstruction
28 and its availability; (3) recommends that third party payers provide coverage and
29 reimbursement for medically necessary breast cancer treatments including but not
30 limited to prophylactic contralateral mastectomy and/or oophorectomy; and (4)
31 recognizes the validity of contralateral breast procedures needed for the achievement
32 of symmetry in size and shape, and urges recognition of these ancillary procedures by
33 Medicare and all other third parties for reimbursement when documentation of medical
34 necessity is provided. (Modify Current HOD Policy)

References:

¹ [Eltahir Y¹](#), [Werners LL](#), [Dreise MM](#), [van Emmichoven IA](#), [Jansen L](#), [Werker PM](#), [de Bock GH](#). Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. [Plast Reconstr Surg](#). 2013 Aug;132(2):201e-209e. doi: 10.1097/PRS.0b013e31829586a7.

Fiscal Note: Minimal - less than \$1,000.

Received: 09/27/18

RELEVANT AMA POLICY

Breast Reconstruction H-55.973

Our AMA: (1) believes that reconstruction of the breast for rehabilitation of the postmastectomy cancer patient should be considered reconstructive surgery rather than aesthetic surgery; (2) supports education for physicians and breast cancer patients on breast reconstruction and its availability; (3) recommends that third party payers provide coverage and reimbursement for medically necessary breast cancer treatments including but not limited to prophylactic contralateral mastectomy and/or oophorectomy; and (4) recognizes the validity of contralateral breast procedures needed for the achievement of symmetry in size and shape, and urges recognition of these ancillary procedures by Medicare and all other third parties for reimbursement when documentation of medical necessity is provided.

CCB/CLRPD Rep. 3, A-14

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 913
(I-18)

Introduced by: Women Physicians Section

Subject: Addressing the Public Health Implications of Pornography

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, Pornography is now recognized as a factor that directly contributes to and increases
2 all forms of violence against women as well as violence against children¹⁻¹⁷; and
3
4 Whereas, Exposure to pornography has been demonstrated to increase the likelihood of
5 perpetration of violence, including rape, domestic violence, and sexual harassment¹⁻¹⁷; and
6
7 Whereas, Literature shows that pornography demonstrably teaches beliefs about women,
8 children, and interpersonal relationships and teaches pathological and/or illegal sexual
9 behaviors (including rape, child molestation, prostitution, domestic violence, pedophilia, sexual
10 harassment, and some paraphilic behaviors)⁴⁻⁷; and
11
12 Whereas, Data demonstrate that pornography normalizes and promotes these pathological
13 and/or illegal behaviors^{1-3, 18-23}; and
14
15 Whereas, Digital access allows average age of first pornography exposure in the early teens
16 during a crucial stage of sexual development in young people⁸⁻¹⁷; and
17
18 Whereas, Pornography can also promote behaviors that increase the risk of sexually
19 transmitted diseases, gastrointestinal fissures/ruptures, post-traumatic stress disorder, sex
20 addiction, and paraphilic behaviors¹⁸⁻²³; and
21
22 Whereas, Four states (Florida, Idaho, Kansas, and Utah) have declared pornography to be a
23 public health risk²⁴; therefore be it
24
25 RESOLVED, That our American Medical Association support efforts to mitigate the negative
26 public health impacts of pornography as it relates to vulnerable populations, including but not
27 limited to women and children. (New HOD Policy)

Fiscal Note: Minimal - less than \$1,000.

Received: 09/28/18

References:

1. Marshall, W. L. (2000). Revisiting the use of pornography by sexual offenders: Implications for theory and practice. *The Journal of Sexual Aggression*, 6, 67-77.
2. Ohbuchi, K., Ikeda, T. & Takeuchi, G. (1994). Effects of violent pornography upon viewers rape myth beliefs: A study of Japanese males. *Psychology, Crime & Law*, 1, 71-81.
3. Allen, M., Emmers, T., Gebhardt, L., & Giery, M. (1995). Exposure to pornography and acceptance of the rape myth. *Journal of Communication*, 45, 1, 5-26.
4. Barak, A., Fisher, W. A., Belfry, S., & Lashambe, D. R. (1999). Sex, guys, and cyberspace: Effects of internet pornography and individual differences on men's attitudes toward women. *Journal of Psychology and Human Sexuality*, 11, 63-92.
5. Shope, J. (2004). When words are not enough: The search for the effect of pornography on abused women. *Violence Against Women*, 10, 1, 56-72.
6. Simmons, C. A., Lehmann, P. & Collier-Tennison, S. (2008). Linking male use of the sex industry to controlling behaviors in violent relationships: An exploratory analysis. *Violence Against Women*, 14, 406-417.
7. Sommers, E. K. & Check, J. V. P. (1987). An empirical investigation of the role of pornography in the verbal and physical abuse of women. *Violence and Victims*, 2(1), 189- 209.
8. Allen, M., D'Alessio, D., & Brezgel, K. (1995). A meta-analysis summarizing the effects of pornography II: Aggression after exposure. *Human Communication Research*, 22, 258- 283.
9. Boeringer, S. B. (1994). Pornography and sexual aggression: Associations of violent and nonviolent depictions with rape and rape proclivity. *Deviant Behavior*, 15, 289-304
10. Baron, L. & Straus, M. (1984). Sexual stratification, pornography, and rape in the United States. In N. Malamuth and E. Donnerstein (Eds) *Pornography and Sexual Aggression*. New York: Academic Press.
11. Bonino, S., Ciairano, S., Rabaglietti, E. & Cattelino, E. (2006). Use of pornography and self-reported engagement in sexual violence among adolescents. *European Journal of Developmental Psychology*, 3 (3), 265-288.
12. Ford, M. & Linney, J. A. (1995). Comparative analysis of juvenile sexual offenders, violent nonsexual offenders and status offenders. *Journal Of Interpersonal Violence*.
13. Marshall, W. L. (1988). The use of sexually explicit stimuli by rapists, child molesters and non-offenders. *Journal of Sex Research*, 25 (2), 267-288.
14. Koss, M., & Oros, C. (1982). Sexual experiences survey: A research instrument investigating sexual aggression and victimization. *Journal of Consulting and Clinical Psychology*, 50, 455-457.
15. Malamuth, N., Addison, T. & Koss, M. (2000). Pornography and sexual aggression: Are there reliable effects and can we understand them? *Annual Review of Sex Research*.
16. Bergen, R. & Bogle, K. (2000). Exploring the connection between pornography and sexual violence. *Violence and Victims*, 15, 3, 227-234.
17. Allen, M., D'Alessio, D., & Brezgel, K. (1995). A meta-analysis summarizing the effects of pornography II: Aggression after exposure. *Human Communication Research*, 22, 258- 283.
18. Weaver, J., Masland, J. L., & Zillmann, D. (1984). Effect of erotica on young men's aesthetic perception of their female sexual partners. *Perceptual and Motor Skills*, 58, 929- 930.
19. Zillmann, D. & Bryant, J. (1988). Pornography's impact on sexual satisfaction. *Journal of Applied Social Psychology*, 18, 438-453.
20. Frable, D. E. S., Johnson, A. E. & Kellman, H. (1997). Seeing masculine men, sexy women and gender differences: Exposure to pornography and cognitive constructs of gender. *Journal of Personality*, 65, 311-355.
21. Carroll, J. S., Padilla-Walker, L. M., Nelson, L. J., Olson, C. D., Barry, C. M., & Madsen, S. (2008). Generation XXX: Pornography acceptance and use among emerging adults. *Journal of Adolescent Research*, 23, 1, 6-30.
22. Zillmann, D. (1989). The effects of prolonged consumption of pornography. In D. Zillmann & J. Bryant (Eds.), *Pornography: Research Advances and Policy Considerations*
23. Zillmann, D & J. Bryant. (1984). Effects of massive exposure to pornography. In Malamuth, N and Donnerstein, E. (Eds), *Pornography and sexual aggression*. San Diego, Academic Press. (pp. 127-158). Hillsdale, NJ: Erlbaum.
24. Is Pornography a 'Public Health Risk'? Available at <https://www.healthline.com/health-news/is-pornography-a-public-health-risk#1>.

RELEVANT AMA POLICY

Child Pornography H-60.990

The AMA (1) encourages and promotes awareness of child pornography issues among physicians; (2) promotes physician awareness of the need for follow-up psychiatric treatment for all victims of child pornography; (3) encourages research on child abuse (including risk factors, psychological and behavioral impact, and treatment efficacy) and dissemination of the findings; and (4) wherever possible, encourages international cooperation among medical societies to be alert to and intervene in child pornography activities.

Citation: BOT Rep. Z, A-88; Reaffirmed: Sunset Report, I-98; Modified and Reaffirmed: CSAPH Rep. 2, A-08; Reaffirmed: CSAPH Rep. 01, A-18

Internet Pornography: Protecting Children and Youth Who Use the Internet and Social Media H-60.934

Our AMA:

- (1) Recognizes the positive role of the Internet in providing health information to children and youth.
- (2) Recognizes the negative role of the Internet in connecting children and youth to predators and exposing them to pornography.
- (3) Supports federal legislation that restricts Internet access to pornographic materials in designated public institutions where children and youth may use the Internet.
- (4) Encourages physicians to continue efforts to raise parent/guardian awareness about the importance of educating their children about safe Internet and social media use.
- (5) Supports school-based media literacy programs that teach effective thinking, learning, and safety skills related to Internet and social media use.

Citation: BOT Rep. 10, I-06; Modified: CSAPH Rep. 01, A-16

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution: 914
(I-18)

Introduced by: American Association of Public Health Physicians

Subject: Common Sense Strategy for Tobacco Control and Harm Reduction

Referred to: Reference Committee K
(Darlyne Menscer, MD, Chair)

1 Whereas, In the last few decades the United States has achieved remarkable success in
2 reducing the use of tobacco products and the associated negative health consequences; and
3
4 Whereas, From a common sense perspective, most would agree that in the case of an
5 individual smoking tobacco vs. e-cigs, the tobacco smoke produces more harmful tars and
6 toxins and individuals have the right to try to switch to e-cigs to reduce inhaling these; and
7
8 Whereas, Many physicians believe that because of the addictive - and possible acute
9 inflammatory effects of nicotine on the cardiovascular system - patients be encouraged to try to
10 stop smoking by other means before using e-cigs; and
11
12 Whereas, Teens and young adults, up to 21 years of age should avoid all nicotine delivery
13 products because of the risks of addiction and adverse effects on brain development; and
14
15 Whereas, The strong divide in the medical and public health communities regarding accessibility
16 of e-cigs, primarily rests on “population” based disagreements and speculations regarding
17 whether they are effective for the complete abstinence from smoking cigarettes, will prove
18 effective over the long term in reducing tobacco use and whether they play a role in addicting
19 youth to nicotine, and possibly tobacco; and
20
21 Whereas, Recent debate over the role of inhalation products in further tobacco harm reduction
22 has created confusion within the profession and public, rather than the sage guidance they
23 deserve; and
24
25 Whereas, E-cigarettes have been shown to be effective in reducing tobacco use in some adults
26 justifying them as a cessation option, yet, it is also prudent to assure minors are banned from
27 purchasing potentially addictive nicotine substances; and
28
29 Whereas, Although abstinence of inhalation of other than prescribed drugs is the healthiest
30 practice, youth continue to experiment with inhalation of substances such as cannabis, corn silk,
31 hookah mixtures and non-drug containing, relatively toxic free, often flavored, “vape” products;
32 therefore be it

1 RESOLVED, That our American Medical Association advocate for a "protect adult choice and
2 youth's health" "common sense" tobacco strategy (with a report back to the House of Delegates
3 annually) under which:

4

- 5 • Current educational, promotional and policy initiatives (e.g. taxation) to reduce the
6 use of tobacco products by inhalation and orally would continue, including
7 advocating for the prohibition of the sale of ALL nicotine containing products to
8 individuals under 21 years unless via prescription for medical purposes.
- 9
- 10 • E-cigarettes (non-tobacco products containing nicotine) would be accessible at an
11 affordable price to adults who wish to use them, and would be available to
12 individuals below 21 years of age only as part of state sanctioned tobacco
13 cessation activities. States and local jurisdictions would be free to require vendors
14 to post warnings regarding the possible health risks of the use of nicotine inhalation
15 products.
- 16
- 17 • Non-nicotine, non-drug containing vaping and other inhalation products would not
18 be considered tobacco products, but would be monitored by state and local
19 jurisdictions as any other personal use product regarding safety and public
20 accommodation. (New HOD Policy)

Fiscal Note: Modest - between \$1,000 - \$5,000.

Received: 09/28/18